



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

- Prior authorization for a non-preferred agent in any class will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance.
- Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.)
- Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified.
- PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc.
- The use of pharmaceutical samples will not be considered when evaluating the members' medical condition or prior prescription history for drugs that require prior authorization.
- Quantity limits may apply. Refer to the Limits List on [the BMS Website](#) by clicking the hyperlink.
- Unless otherwise indicated, non-preferred combination products require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred single-ingredient agents.
- Acronyms
  - CL - Requires clinical PA. For detailed clinical criteria, please go to the [PA criteria](#) page by clicking the hyperlink.
  - NR – Denotes a new drug which has not yet been reviewed by the P & T Committee. **These agents are available only on appeal to the BMS Medical Director.**
  - AP - Non-preferred and selected preferred drugs, where indicated, are subject to auto-PA criteria. See PA criteria column.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

<b>CLASSES CHANGING</b>	<b>Status Changes</b>	<b>PA Criteria Changes</b>	<b>New Drugs</b>
ACNE AGENTS, TOPICAL	XXXX		XXXX
ANTIBIOTICS, VAGINAL	XXXX		
ANTIHYPERURICEMICS	XXXX		
ANTIMIGRAINE AGENTS, PROPHYLAXIS	XXXX		XXXX
ANTIRETROVIRALS			XXXX
ANTICONVULSANTS			XXXX
BRONCHODILATORS, BETA AGONIST	XXXX		
CYTOKINE & CAM ANTAGONISTS	XXXX		
GLUCOCORTICOIDS, INHALED	XXXX		
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS	XXXX		
HYPOGLYEMICS, SGLT2 INHIBITORS			XXXX
IMMUNOMODULATORS, ATOPIC DERMATITIS	XXXX		XXXX
IRRITABLE BOWEL SYNDROME/SELECT GI AGENTS	XXXX		XXXX
LAXATIVES AND CATHARTICS			XXXX
LIPOTROPTICS, OTHER (NON-STATINS)			XXXX
MABS, ANTI-IL/IgE	XXXX		
MULTIPLE SCLEROSIS AGENTS	XXXX		
NEUROPATHIC PAIN	XXXX		
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS			XXXX
OTIC ANTIBIOTICS			XXXX
SEDATIVE HYPNOTICS			XXXX
STEROIDS, TOPICAL	XXXX		
STIMULANTS AND RELATED AGENTS	XXXX		XXXX



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ACNE AGENTS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of one (1) preferred retinoid and two (2) unique chemical entities in two (2) other subclasses, including the generic version of the requested non-preferred product, before they will be approved, unless one (1) of the exceptions on the PA form is present.		
In cases of pregnancy, a trial of retinoids will <i>not</i> be required. For members eighteen (18) years of age or older, a trial of retinoids will <i>not</i> be required. Acne kits are non-preferred.		
<b>Specific Criteria for sub-class will be listed below.</b> NOTE: Non-preferred agents in the Rosacea sub-class are available <u>only on appeal</u> and require at least a 30-day trial of all preferred agents in that sub-class.		
<b>ANTI-INFECTIVE</b>		
<p>ACZONE (dapsone) CLINDAGEL (clindamycin) clindamycin lotion, medicated swab, solution erythromycin gel, solution</p>	<p>AKNE-MYCIN (erythromycin) ARAZLO (tazarotene) AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDACIN ETZ kit, medicated swab (clindamycin) CLINDACIN P (clindamycin) CLINDACIN PAC (clindamycin) clindamycin gel, foam dapsone ERYGEL (erythromycin) erythromycin medicated swab EVOCLIN (clindamycin) FABIOR (tazarotene) KLARON (sulfacetamide) OVACE/PLUS (sulfacetamide) sodium sulfacetamide 10% cleansing gel sulfacetamide cleanser sulfacetamide cleanser ER sulfacetamide shampoo sulfacetamide suspension</p>	
<b>RETINOIDS</b>		
<p>DIFFERIN (adapalene) RETIN-A (tretinoin) RETIN-A MICRO (tretinoin) TAZORAC (tazarotene)</p>	<p>adapalene AKLIEF CREAM (trifarotene) ALTRENO LOTION (tretinoin) ATRALIN (tretinoin)</p>	<p><b>In addition to the Class Criteria:</b> PA required for members eighteen (18) years of age or older.</p>



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	AVITA (tretinoin) PLIXDA SOLUTION (adapalene) tazarotene cream <b>tretinoin cream, gel</b> tretinoin gel micro	
<b>KERATOLYTICS</b>		
benzoyl peroxide cleanser Rx & OTC, 10% cream OTC, gel Rx & OTC, lotion OTC, wash OTC PANOXYL-4 OTC (benzoyl peroxide)	BENZEFOAM ULTRA (benzoyl peroxide) BP 10-1 (benzoyl peroxide) <b>BPO (benzoyl peroxide)</b> PANOXYL-8 OTC (benzoyl peroxide) SULPHO-LAC (sulfur)	
<b>COMBINATION AGENTS</b>		
<b>ACANYA (clindamycin phosphate/benzoyl peroxide)</b> <b>BENZAMYCIN PAK (benzoyl peroxide/erythromycin)</b> benzoyl peroxide/clindamycin gel (generic DUAC only) EPIDUO (adapalene/benzoyl peroxide)* EPIDUO FORTE (adapalene/benzoyl peroxide)* <b>ONEXTON (clindamycin phosphate/benzoyl peroxide)</b> <b>sulfacetamide sodium/sulfur suspension</b> <b>ZIANA (clindamycin/tretinoin)*</b>	<b>adapalene-benzoyl peroxide</b> AVAR/-E/LS (sulfur/sulfacetamide) BENZACLIN GEL (benzoyl peroxide/clindamycin) benzoyl peroxide/clindamycin gel (all generics other than DUAC) benzoyl peroxide/urea CERISA (sulfacetamide sodium/sulfur) CLARIFOAM EF (sulfacetamide/sulfur) CLENIA (sulfacetamide sodium/sulfur) <b>clindamycin-tretinoin gel</b> DUAC (benzoyl peroxide/clindamycin) <b>erythromycin/benzoyl peroxide</b> NEUAC (clindamycin phosphate/benzoyl peroxide) PRASCION (sulfacetamide sodium/sulfur) SE 10-5 SS (sulfacetamide/sulfur) SSS 10-4 (sulfacetamide /sulfur) SSS 10-5 foam (sulfacetamide /sulfur) sulfacetamide sodium/sulfur cloths, lotion, pads sulfacetamide/sulfur wash/cleanser sulfacetamide/sulfur wash kit sulfacetamide sodium/sulfur/ urea SUMADAN/XLT (sulfacetamide/sulfur) SUMAXIN/TS (sulfacetamide sodium/sulfur) VELTIN (clindamycin/tretinoin)*	<b>In addition to the Class Criteria:</b> Non-preferred combination agents require thirty (30) day trials of the corresponding preferred single agents before they will be approved.  *PA required for combination agents with Retinoid products for members eighteen (18) years of age or older.
<b>ROSACEA AGENTS</b>		
FINACEA GEL (azelaic acid)	AMZEEQ FOAM (minocycline)	<b>Subclass criteria:</b> Non-preferred agents are available only on



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
MIRVASO GEL (brimonidine) metronidazole cream metronidazole gel 0.75% (NDCs 00115-1474-46, 00168-0275-45, 51672-4116-06, 66993-0962-45 only)	FINACEA FOAM (azelaic acid) METROCREAM (metronidazole) METROGEL GEL (metronidazole) METROLOTION (metronidazole) metronidazole lotion metronidazole gel (all other NDCs) NORITATE CREAM (metronidazole) RHOFADÉ (oxymetazoline) ROSADAN (metronidazole) SOOLANTRA CREAM (ivermectin)	appeal and require evidence of 30-day trials of all chemically-unique preferred agents in the sub-class.
<b>ALZHEIMER'S AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.		
Prior authorization is required for members up to forty-five (45) years of age if there is no diagnosis of Alzheimer's disease.		
<b>CHOLINESTERASE INHIBITORS</b>		
donepezil 5 and 10 mg donepezil ODT	ARICEPT (donepezil) donepezil 23 mg* EXELON CAPSULE (rivastigmine) EXELON PATCH (rivastigmine) galantamine galantamine ER RAZADYNE (galantamine) RAZADYNE ER (galantamine) rivastigmine	*Donepezil 23 mg tablets will be authorized if the following criteria are met: <ol style="list-style-type: none"> <li>1. There is a diagnosis of moderate-to-severe Alzheimer's Disease <b>and</b></li> <li>2. There has been a trial of donepezil 10 mg daily for at least three (3) months and donepezil 20 mg daily for an additional one (1) month.</li> </ol>
<b>NMDA RECEPTOR ANTAGONIST</b>		
memantine	memantine ER memantine solution NAMENDA (memantine) NAMENDA XR (memantine)*	*Namenda XR requires ninety (90) days of compliant therapy with Namenda.
<b>CHOLINESTERASE INHIBITOR/NMDA RECEPTOR ANTAGONIST COMBINATIONS</b>		
	NAMZARIC (donepezil/memantine)	Combination agents require thirty (30) day trials of each corresponding preferred single agent.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANALGESICS, NARCOTIC LONG ACTING (Non-parenteral)<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require six (6) day trials of two (2) chemically distinct preferred agents <b>AND</b> a six (6) day trial of the generic form of the requested non-preferred agent (if available) before they will be approved, unless one (1) of the exceptions on the PA form is present. If no generic form is available for the requested non-preferred brand agent, then another generic non-preferred agent must be trialed instead. <b>NOTE: All long-acting opioid agents require a prior authorization for children under 18 years of age.</b> Requests must be for an FDA approved age and indication and specify previous opioid and non-opioid therapies attempted.		
BUTRANS (buprenorphine) fentanyl transdermal 12, 25, 50, 75, 100 mcg/hr morphine ER tablets tramadol ER tablets (generic Ultram ER)	ARYMO ER (morphine sulfate) BELBUCA (buprenorphine buccal film)* buprenorphine patch (all labelers including 00093) CONZIP ER (tramadol) DOLOPHINE (methadone) DURAGESIC (fentanyl) EMBEDA (morphine/naltrexone) EXALGO ER (hydromorphone) fentanyl transdermal 37.5, 62.5, 87.5 mcg/hr hydromorphone ER HYSINGLA ER (hydrocodone) KADIAN (morphine) LAZANDA SPRAY (fentanyl) methadone** MORPHABOND ER (morphine sulfate) morphine ER capsules (generic for Avinza) morphine ER capsules (generic for Kadian) MS CONTIN (morphine) NUCYNTA ER (tapentadol) OPANA ER (oxymorphone) oxycodone ER** OXYCONTIN (oxycodone) oxymorphone ER** tramadol ER (generic Conzip ER)*** ULTRAM ER (tramadol) XARTEMIS XR (oxycodone/acetaminophen) XTAMPZA ER (oxycodone) ZOHYDRO ER (hydrocodone)	*Belbuca prior authorization requires manual review. Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Methadone, oxycodone ER and oxymorphone ER will be authorized without a trial of the preferred agents if a diagnosis of cancer is submitted.  ***Tramadol ER (generic Conzip) requires a manual review and may be authorized for ninety (90) days with submission of a detailed treatment plan including anticipated duration of treatment and scheduled follow-ups with the prescriber.



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANALGESICS, NARCOTIC SHORT ACTING (Non-parenteral)<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require six (6) day trials of at least four (4) chemically distinct preferred agents (based on the narcotic ingredient only), including the generic formulation of the requested non-preferred agent, before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>NOTE: All tramadol and codeine products require a prior authorization for children under 18 years of age.</b> Requests must be for an FDA approved age and indication and specify non-opioid therapies attempted.		
APAP/codeine butalbital/APAP/caffeine/codeine codeine hydrocodone/APAP 2.5/325 mg, 5/325 mg, 7.5/325 mg, 10/325 mg hydrocodone/APAP solution hydrocodone/ibuprofen hydromorphone tablets LORTAB SOLUTION (hydrocodone/acetaminophen) morphine oxycodone tablets, concentrate, solution oxycodone/APAP oxycodone/ASA pentazocine/naloxone tramadol tramadol/APAP	ABSTRAL (fentanyl) ACTIQ (fentanyl) butalbital/ASA/caffeine/codeine butorphanol CAPITAL W/CODEINE (APAP/codeine) DEMEROL (meperidine) dihydrocodeine/ APAP/caffeine DILAUDID (hydromorphone) fentanyl FENTORA (fentanyl) FIORICET W/ CODEINE (butalbital/APAP/caffeine/codeine) FIORINAL W/ CODEINE (butalbital/ASA/caffeine/codeine) hydrocodone/APAP 5/300 mg, 7.5/300 mg, 10/300 mg hydromorphone liquid, suppositories IBUDONE (hydrocodone/ibuprofen) LAZANDA (fentanyl) levorphanol LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP) meperidine NORCO (hydrocodone/APAP) NUCYNTA (tapentadol) ONSOLIS (fentanyl) OPANA (oxymorphone) OXECTA (oxycodone) oxycodone capsules oxycodone/ibuprofen oxymorphone PERCOCET (oxycodone/APAP) PRIMLEV (oxycodone/APAP) REPRESXAIN (hydrocodone/ibuprofen) ROXICODONE (oxycodone)	Fentanyl buccal, nasal and sublingual products will only be authorized for a diagnosis of cancer and as an adjunct to a long-acting agent. These dosage forms will not be authorized for monotherapy.  <b>Limits:</b> Unless the patient has escalating cancer pain or another diagnosis supporting increased quantities of short-acting opioids, all short acting solid forms of the narcotic analgesics are limited to 120 tablets per thirty (30) days. Longer-acting medications should be maximized to prevent unnecessary breakthrough pain in chronic pain therapy.  Immediate-release tramadol is limited to 240 tablets per thirty (30) days.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ROXYBOND (oxycodone) RYBIX ODT (tramadol) SUBSYS (fentanyl) SYNALGOS-DC (dihydrocodeine/ASA/ caffeine) TYLENOL W/CODEINE (APAP/codeine) ULTRACET (tramadol/APAP) ULTRAM (tramadol) VERDROCET (hydrocodone/APAP) VICODIN (hydrocodone/APAP) VICOPROFEN (hydrocodone/ibuprofen) XODOL (hydrocodone/acetaminophen) XYLON (hydrocodone/ibuprofen) ZAMICET (hydrocodone/APAP)	
<b>ANDROGENIC AGENTS</b>		
<b>CLASS PA CRITERIA:</b> A non-preferred agent will only be authorized if one (1) of the exceptions on the PA form is present.		
ANDRODERM (testosterone) ANDROGEL (testosterone) METHITEST (methyltestosterone) testosterone cypionate vial <sup>CL</sup> testosterone enanthate vial <sup>CL</sup>	ANDROID (methyltestosterone) AVEED VIAL (testosterone undecanoate) AXIRON (testosterone) FORTESTA (testosterone) JATENZO (testosterone undecanoate) methyltestosterone capsule NATESTO (testosterone) STRIANT BUCCAL (testosterone) TESTIM (testosterone) TESTRED (methyltestosterone) testosterone gel VOGELXO (testosterone) XYOSTED (testosterone enanthate)	
<b>ANESTHETICS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require ten (10) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
lidocaine lidocaine/prilocaine xylocaine	LIDAMANTLE (lidocaine) LIDAMANTLE HC (lidocaine/hydrocortisone) lidocaine/hydrocortisone LIDOTRAL CREAM (lidocaine) LIDOZION LOTION (lidocaine) SYNERA (lidocaine/tetracaine) VOPAC MDS (ketoprofen/lidocaine)	





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANGIOTENSIN MODULATORS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require fourteen (14) day trials of each preferred agent in the same sub-class, with the exception of the Direct Renin Inhibitors, before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>ACE INHIBITORS</b>		
benazepril captopril enalapril fosinopril lisinopril quinapril ramipril	ACCUPRIL (quinapril) ACEON (perindopril) ALTACE (ramipril) EPANED (enalapril)* LOTENSIN (benazepril) MAVIK (trandolapril) moexipril perindopril PRINIVIL (lisinopril) QBRELIS SOLUTION (lisinopril)** trandolapril UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril)	*Epaned will be authorized with a diagnosis of hypertension, symptomatic heart failure or asymptomatic left ventricular dysfunction provided that the patient is less than seven (7) years of age <b>OR</b> is unable to ingest a solid dosage form due to documented oral-motor difficulties or dysphagia.  **Qbrelis solution may be authorized for children ages 6-10 who are unable to tolerate a solid dosage form. Qbrelis may also be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.
<b>ACE INHIBITOR COMBINATION DRUGS</b>		
benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LOTENSIN HCT (benazepril/HCTZ) LOTREL (benazepril/amlodipine) moexipril/HCTZ PRESTALIA (perindopril/amlodipine) PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) trandolapril/verapamil VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	
<b>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)</b>		
irbesartan losartan valsartan olmesartan	ATACAND (candesartan) AVAPRO (irbesartan) BENICAR (olmesartan) candesartan COZAAR (losartan) DIOVAN (valsartan) EDARBI (azilsartan) eprosartan	



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	MICARDIS (telmisartan) telmisartan	
<b>ARB COMBINATIONS</b>		
ENTRESTO (valsartan/sacubitril) <sup>AP*</sup> irbesartan/HCTZ losartan/HCTZ olmesartan/amlodipine olmesartan/HCTZ TRIBENZOR (olmesartan/amlodipine/HCTZ) TWYNSTA (telmisartan/amlodipine) valsartan/amlodipine valsartan/amlodipine/HCTZ valsartan/HCTZ	ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) AZOR (olmesartan/amlodipine) BENICAR-HCT (olmesartan/HCTZ) BYVALSON (nebivolol/valsartan) candesartan/HCTZ DIOVAN-HCT (valsartan/HCTZ) EDARBYCLOR (azilsartan/chlorthalidone) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) olmesartan/amlodipine/HCTZ telmisartan/amlodipine telmisartan HCTZ	*Entresto will only be authorized for patients 18 years of age or older who are diagnosed with chronic heart-failure.
<b>DIRECT RENIN INHIBITORS</b>		
	AMTURNIDE (aliskiren/amlodipine/HCTZ) TEKAMLO (aliskiren/amlodipine) TEKTURNA (aliskiren) TEKTURNA HCT (aliskiren/HCTZ) VALTURNA (aliskiren/valsartan)	<b>Substitute for Class Criteria:</b> Tekturina requires a thirty (30) day trial of one (1) preferred ACE, ARB, or combination agent, at the maximum tolerable dose, before it will be authorized unless one (1) of the exceptions on the PA form is present.  Amturnide, Tekamlo, Tekturina HCT or Valturna will be authorized if the criteria for Tekturina are met and the patient also needs the other agents in the combination.
<b>ANTIANGINAL &amp; ANTI-ISCHEMIC</b>		
<b>CLASS PA CRITERIA:</b> Agents in this class may only be authorized for patients with angina who are also taking a calcium channel blocker, a beta blocker, or a nitrite as single agents or a combination agent containing one (1) of these ingredients.		
ranolazine <sup>AP</sup>	RANEXA	
<b>ANTIBIOTICS, GI &amp; RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a fourteen (14) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
FIRVANQ (vancomycin) metronidazole tablet neomycin tinidazole	DIFICID (fidaxomicin)* FLAGYL (metronidazole) FLAGYL ER (metronidazole ER) metronidazole capsule paromomycin	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TINDAMAX (tinidazole) VANCOGIN (vancomycin) vancomycin XIFAXAN (rifaximin)*	
<b>ANTIBIOTICS, INHALED</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a twenty-eight (28) day trial of a preferred agent and documentation of therapeutic failure before they will be approved, unless one (1) of the exceptions on the PA form is present.		
BETHKIS (tobramycin) KITABIS PAK (tobramycin)	CAYSTON (aztreonam) TOBI (tobramycin) TOBI PODHALER (tobramycin) tobramycin	
<b>ANTIBIOTICS, TOPICAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require ten (10) day trials of at least one preferred agent, including the generic formulation of the requested non-preferred agent, before they will be approved, unless one (1) of the exceptions on the PA form is present.		
bacitracin (Rx, OTC) gentamicin sulfate mupirocin ointment	BACTROBAN (mupirocin) CENTANY (mupirocin) CORTISPORIN (bacitracin/neomycin/polymyxin/Hc) mupirocin cream neomycin/polymyxin/pramoxine XEPI CREAM (ozenoxacin)	
<b>ANTIBIOTICS, VAGINAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require trials of each chemically unique preferred agent at the manufacturer's recommended duration, before they will be approved, unless one (1) of the exceptions on the PA form is present.		
CLEOCIN OVULE (clindamycin) CLINDESSE (clindamycin) metronidazole NUVESSA (metronidazole)	AVC (sulfanilamide) CLEOCIN CREAM (clindamycin) clindamycin cream METROGEL (metronidazole) SOLOSEC (secnidazole) VANDAZOLE (metronidazole)	
<b>ANTICOAGULANTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a trial of each preferred agent in the same sub-class, unless one (1) of the exceptions on the PA form is present.		
<b>INJECTABLE<sup>CL</sup></b>		
enoxaparin	ARIXTRA (fondaparinux) fondaparinux FRAGMIN (dalteparin)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LOVENOX (enoxaparin)	
<b>ORAL</b>		
COUMADIN (warfarin) ELIQUIS (apixaban) PRADAXA (dabigatran) warfarin XARELTO (rivaroxaban)	SAVAYSA (edoxaban)	
<b>ANTICONSULSANTS</b>		
<p><b>CLASS PA CRITERIA:</b> For a diagnosis of seizure disorder, non-preferred agents require a fourteen (14) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present; patients currently on established therapies shall be grandfathered.</p> <p>For all other diagnoses, non-preferred agents require a thirty (30) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.</p> <p>In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription for the brand name product to be reimbursed.</p>		
<b>ADJUVANTS</b>		
carbamazepine carbamazepine ER carbamazepine XR divalproex divalproex ER divalproex sprinkle EPITOL (carbamazepine) GABITRIL (tiagabine) lamotrigine levetiracetam IR levetiracetam ER levetiracetam IR suspension oxcarbazepine suspension and tablets TEGRETOL SUSPENSION (carbamazepine) topiramate IR topiramate ER* valproic acid VIMPAT (lacosamide) zonisamide	APTIOM (eslicarbazepine) BANZEL (rufinamide) BRIVIACT (brivaracetam) carbamazepine oral suspension carbamazepine XR CARBATROL (carbamazepine) DEPAKENE (valproic acid) DEPAKOTE (divalproex) DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) EQUETRO (carbamazepine) FANATREX SUSPENSION (gabapentin) felbamate FELBATOL (felbamate) FYCOMPA (perampanel) KEPPRA (levetiracetam) KEPPRA SOLUTION (levetiracetam) KEPPRA XR (levetiracetam) LAMICTAL (lamotrigine) LAMICTAL CHEWABLE (lamotrigine)	*Topiramate ER will be authorized after a thirty (30) day trial of topiramate IR.  **Qudexy XR and Trokendi XR are only approvable on appeal.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LAMICTAL ODT (lamotrigine) LAMICTAL XR (lamotrigine) lamotrigine dose pack lamotrigine ER OXTELLAR XR (oxcarbazepine) POTIGA (ezogabine) QUDEXY XR (topiramate ER)** SABRIL (vigabatrin) SPRITAM (levetiracetam) STAVZOR (valproic acid) TEGRETOL TABLETS (carbamazepine) TEGRETOL XR (carbamazepine) tiagabine TOPAMAX (topiramate) TRILEPTAL SUSPENSION and TABLETS (oxcarbazepine) TROKENDI XR (topiramate)** <b>XCOPRI (cenobamate)</b> ZONEGRAN (zonisamide)	
<b>BARBITURATES<sup>AP</sup></b>		
phenobarbital primidone	MYSOLINE (primidone)	
<b>BENZODIAZEPINES<sup>AP</sup></b>		
clonazepam diazepam rectal gel diazepam tablets NAYZILAM NASAL SPRAY (midazolam) VALTOCO NASAL SPRAY (diazepam)	clobazam* clonazepam ODT DIASTAT (diazepam rectal) KLONOPIN (clonazepam) ONFI (clobazam)* ONFI SUSPENSION (clobazam)* SYMPAZAN (clobazam film)*	*Onfi shall be authorized as adjunctive therapy for treatment of Lennox-Gastaut Syndrome without further restrictions. Off-label use requires an appeal to the Medical Director. NOTE: generic clobazam is preferred over brand ONFI.
<b>CANNABINOIDS</b>		
	EPIDIOLEX SOLUTION (cannabidiol)*	* Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>HYDANTOINS<sup>AP</sup></b>		
DILANTIN (phenytoin sodium, extended) PEGANONE (ethotoin) phenytoin capsules, chewable tablets, suspension	DILANTIN INFATABS (phenytoin) PHENYTEK (phenytoin)	
<b>SUCCINIMIDES</b>		
CELONTIN (methsuximide)	ZARONTIN (ethosuximide) capsules	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ethosuximide capsules ethosuximide syrup	ZARONTIN (ethosuximide) syrup	
<b>ANTIDEPRESSANTS, OTHER</b>		
CLASS PA CRITERIA: See below for individual sub-class criteria.		
<b>MAOIs<sup>AP</sup></b>		
	MARPLAN (isocarboxazid) NARDIL (phenelzine) PARNATE (tranylcypromine) phenelzine tranylcypromine	Patients stabilized on MAOI agents will be grandfathered.
<b>SNRIS<sup>AP</sup></b>		
duloxetine capsules venlafaxine ER capsules	CYMBALTA (duloxetine) desvenlafaxine ER desvenlafaxine fumarate ER EFFEXOR XR (venlafaxine) FETZIMA (levomilnacipran) KHEDEZLA (desvenlafaxine) PRISTIQ (desvenlafaxine) venlafaxine IR VENLAFAXINE ER TABLETS (venlafaxine)	Non-preferred agents require separate thirty (30) day trials of a preferred agent in this sub-class <b>AND</b> an SSRI before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>SECOND GENERATION NON-SSRI, OTHER<sup>AP</sup></b>		
bupropion IR bupropion SR bupropion XL mirtazapine trazodone	APLENZIN (bupropion hbr) EMSAM (selegiline) FORFIVO XL (bupropion) nefazodone OLEPTRO ER (trazodone) REMERON (mirtazapine) TRINTELLIX (vortioxetine) VIIBRYD (vilazodone HCl) WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion)	Non-preferred agents require separate thirty (30) day trials of a preferred agent in this sub-class <b>AND</b> an SSRI before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>SELECTED TCAs</b>		
imipramine HCl	imipramine pamoate TOFRANIL (imipramine HCl) TOFRANIL PM (imipramine pamoate)	Non-preferred agents require a twelve (12) week trial of imipramine HCl before they will be approved, unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIDEPRESSANTS, SSRIs<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of at least two (2) preferred agents before they will be approved, unless one (1) of the exceptions on the PA form is present.		
Upon hospital discharge, patients admitted with a primary mental health diagnosis who have been stabilized on a non-preferred SSRI will receive an authorization to continue that drug.		
citalopram escitalopram tablets fluoxetine capsules, solution fluvoxamine paroxetine sertraline	BRISDELLE (paroxetine) CELEXA (citalopram) escitalopram solution fluoxetine tablets fluvoxamine ER LEXAPRO (escitalopram) LUVOX CR (fluvoxamine) paroxetine 7.5 mg capsules paroxetine ER PAXIL (paroxetine) PAXIL CR (paroxetine) PEKEVA (paroxetine) PROZAC (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	
<b>ANTIEMETICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for sub-class criteria.		
<b>5HT<sub>3</sub> RECEPTOR BLOCKERS</b>		
granisetron ondansetron ODT, solution, tablets	ANZEMET (dolasetron) GRANISOL (granisetron) ondansetron vials SANCUSO (granisetron) SUSTOL (granisetron) ZOFRAN (ondansetron) ZUPLLENZ (ondansetron)	Non-preferred agents require a three (3) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>CANNABINOIDS</b>		
	CESAMET (nabilone)* dronabinol** MARINOL (dronabinol)** SYNDROS SOLUTION (dronabinol)**	*Cesamet will be authorized only for the treatment of nausea and vomiting associated with cancer chemotherapy for patients who have failed to respond adequately to three (3) day trials of conventional treatments such as promethazine or ondansetron and are eighteen (18) years of age or older.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		**Dronabinol will only be authorized for: 1. The treatment of anorexia associated with weight loss in patients with AIDS or cancer and unresponsive to megestrol <b>or</b> 2. The prophylaxis of chemotherapy induced nausea and vomiting unresponsive to three (3) day trials of ondansetron or promethazine for patients from eighteen (18) up to sixty-five (65) years of age.
<b>SUBSTANCE P ANTAGONISTS</b>		
EMEND (aprepitant)	aprepitant VARUBI (rolapitant)	Non-preferred agents require a three (3) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>COMBINATIONS</b>		
	AKYNZEO (netupitant/palonosetron) BONJESTA (doxylamine/pyridoxine) DICLEGIS (doxylamine/pyridoxine)	Non-preferred agents will only be approved on appeal.
<b>ANTIFUNGALS, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be authorized if one (1) of the exceptions on the PA form is present.		
clotrimazole fluconazole* nystatin terbinafine <sup>CL</sup>	ANCOBON (flucytosine) CRESEMBA (isovuconazonium) <sup>CL**</sup> DIFLUCAN (fluconazole) flucytosine griseofulvin <sup>***</sup> GRIS-PEG (griseofulvin) itraconazole ketoconazole <sup>****</sup> LAMISIL (terbinafine) MYCELEX (clotrimazole) NIZORAL (ketoconazole) NOXAFIL (posaconazole) ONMEL (itraconazole) ORAVIG (miconazole) SPORANOX (itraconazole) TOLSURA (itraconazole) VFEND (voriconazole) voriconazole suspension voriconazole tablets	*PA is required when limits are exceeded.  **Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  ***PA is not required for griseofulvin suspension for children up to eighteen (18) years of age for the treatment of tinea capitis.  ****Ketoconazole will be authorized if the following criteria are met: 1. Diagnosis of one of the following fungal infections: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, or paracoccidioidomycosis <b>and</b> 2. Documented failure or intolerance of all other diagnosis-appropriate antifungal therapies, i.e. itraconazole, fluconazole, flucytosine, etc <b>and</b> 3. Baseline assessment of the liver status including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, prothrombin time, and international normalized ratio (INR) before





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIFUNGALS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require fourteen (14) day trials of two (2) preferred agents before they will be approved, unless one (1) of the exceptions on the PA form is present. If a non-preferred shampoo is requested, a fourteen (14) day trial of one (1) preferred product (i.e. ketoconazole shampoo) is required.		
<b>ANTIFUNGALS</b>		
econazole ketoconazole cream, shampoo MENTAX (butenafine) miconazole (OTC) nystatin	CICLODAN (ciclopirox) ciclopirox ERTACZO (sertaconazole) EXELDERM (sulconazole) EXTINA (ketoconazole) GYNAZOLE 1 CREAM (butoconazole) JUBLIA (efinaconazole) ketoconazole foam KERYDIN (tavaborole) KETODAN (ketoconazole) LOPROX (ciclopirox) LUZU (luliconazole) MYCOSTATIN (nystatin) NAFTIN CREAM (naftifine) NAFTIN GEL (naftifine) NIZORAL (ketoconazole) OXISTAT (oxiconazole)* PEDIPIROX-4 (ciclopirox) PENLAC (ciclopirox) VUSION (miconazole/petrolatum/zinc oxide)	starting treatment <b>and</b> 4. Weekly monitoring of serum ALT for the duration of treatment (If ALT values increase to a level above the upper limit of normal or 30% above baseline, or if the patient develops symptoms of abnormal liver function, treatment should be interrupted and a full set of liver tests be obtained. Liver tests should be repeated to ensure normalization of values.) <b>and</b> 5. Assessment of all concomitant medications for potential adverse drug interactions with ketoconazole. <b>Ketoconazole will not be authorized for treatment for fungal infections of the skin and nails.</b>  *Oxistat cream will be authorized for children up to thirteen (13) years of age for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIFUNGAL/STEROID COMBINATIONS</b>		
clotrimazole/betamethasone cream	clotrimazole/betamethasone lotion KETOCON PLUS (ketoconazole/hydrocortisone) LOTRISONE (clotrimazole/betamethasone) nystatin/triamcinolone	
<b>ANTIHEMOPHILIA FACTOR AGENTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> All agents will require prior-authorization, and non-preferred agents require medical reasoning explaining why the need cannot be met using a preferred product.		
All currently established regimens shall be grandfathered with documentation of adherence to therapy.		
<b>FACTOR VIII</b>		
ADVATE AFSTYLA ALPHANATE HELIXATE FS HEMOFIL M HUMATE-P KOATE KOATE-DVI KOGENATE FS MONOCLATE-P NOVOEIGHT NUWIQ WILATE XYNTHA XYNTHA SOLOFUSE	ADYNOVATE ELOCTATE ESPEROCT JIVI KOVALTRY RECOMBINATE VONVENDI	
<b>FACTOR IX</b>		
ALPHANINE SD ALPROLIX BEBULIN BENEFIX IXINITY MONONINE PROFILNINE RIXUBIS	IDELVION REBINYN	
<b>FACTOR IXa/IX</b>		
	HEMLIBRA (emicizumab-kxwh)*	*Hemlibra shall be approved without further restriction for patients with Hemophilia A with documented presence of



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		Factor VIII inhibitors.
<b>ANTIHYPERTENSIVES, SYMPATHOLYTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred unique chemical entity in the corresponding formulation before they will be approved, unless one (1) of the exceptions on the PA form is present.		
CATAPRES-TTS (clonidine) clonidine patch clonidine tablets	CATAPRES TABLETS (clonidine) NEXICLON XR (clonidine)	
<b>ANTIHYPERTENSIVES, SYMPATHOLYTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of one (1) of the preferred agents for the prevention of gouty arthritis attacks (colchicine/probenecid, probenecid, or allopurinol) before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>ANTIMITOTICS</b>		
<b>COLCRYS (colchicine)</b>	<b>colchicine capsules</b> colchicine tablets MITIGARE (colchicine) GLOPERBA (colchicine)	In the case of acute gouty attacks, a ten (10) day supply (twenty (20) capsules) of the preferred agent(s) in this subclass will be authorized per ninety (90) days.  Gloperba may only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.
<b>ANTIMITOTIC-URICOSURIC COMBINATION</b>		
colchicine/probenecid		
<b>URICOSURIC</b>		
probenecid	ZURAMPIC (lesinurad)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>XANTHINE OXIDASE INHIBITORS</b>		
allopurinol	ULORIC (febuxostat) ZYLOPRIM (allopurinol)	
<b>URICOSURIC – XANTHINE OXIDASE INHIBITORS</b>		
	DUZALLO (allopurinol/lesinurad)	Non-preferred agents will only be approved on appeal.
<b>ANTIMIGRAINE AGENTS, PROPHYLAXIS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> All agents require a prior authorization. Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink. Non-preferred agents require a 90-day trial of all preferred agents.		
AIMOVIG (erenumab) <b>AJOVY (fremanezumab)</b>	<b>EMGALITY (galcanezumab) 120mg/mL</b> EMGALITY (galcanezumab) 300mg/3 mL*	*Emgality 300 mg/3 mL requires review by the Medical Director and is available only on appeal.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	Vyepti (eptinezumab)	
<b>ANTIMIGRAINE AGENTS, ACUTE<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three (3) day trials of each preferred unique chemical entity as well as a three (3) day trial using the same route of administration as the requested agent (if available), before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>TRIPTANS</b>		
naratriptan rizatriptan ODT rizatriptan tablet sumatriptan injection <sup>CL</sup> sumatriptan nasal spray sumatriptan tablets	almotriptan AMERGE (naratriptan) AXERT (almotriptan) eletriptan FROVA (frovatriptan) frovatriptan IMITREX INJECTION (sumatriptan) <sup>CL</sup> IMITREX NASAL SPRAY (sumatriptan) IMITREX tablets (sumatriptan) MAXALT MLT (rizatriptan) MAXALT (rizatriptan) ONZETRA XSAIL (sumatriptan)* RELPAX (eletriptan) SUMAVEL (sumatriptan) TOSYMRA NASAL SPRAY (sumatriptan)* ZECUITY PATCH (sumatriptan) ZEMBRACE SYMTOUCH (sumatriptan) zolmitriptan zolmitriptan ODT ZOMIG (zolmitriptan) ZOMIG ZMT (zolmitriptan)	<b>*In addition to the Class Criteria:</b> Onzetra Xsail and Tosymra require three (3) day trials of each preferred oral, nasal and injectable forms of sumatriptan.
<b>TRIPTAN COMBINATIONS</b>		
	TREXIMET (sumatriptan/naproxen sodium)	
<b>OTHER</b>		
NURTEC ODT (rimegepant)	CAMBIA (diclofenac) UBRELVY (ubrogepant) REYVOW (lasmiditan)	<b>*Nurtec ODT</b> requires three (3) day trials of two (2) preferred chemically distinct triptans before it may be approved, unless one (1) of the exceptions on the PA form is present.  <b>**Ubrelvy and Reyvow</b> require three (3) day trials of two (2) preferred chemically distinct triptans as well as a three (3) day trial of Nurtec ODT before they may be approved, unless one (1) of the exceptions on the PA form is present.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIPARASITICS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require trials of each preferred agent (which are age and weight appropriate) before they will be approved, unless one (1) of the exceptions on the PA form is present.		
NATROBA (spinosad) permethrin 5% cream pyrethrins-piperonyl butoxide OTC	ELIMITE CREAM (permethrin) EURAX (crotamiton) LICE EGG REMOVER OTC (benzalkonium chloride) lindane malathion OVIDE (malathion) SKLICE (ivermectin) spinosad VANALICE (piperonyl/pyrethin)	
<b>ANTIPARKINSON'S AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Patients starting therapy on drugs in this class must show a documented allergy to all preferred agents in the corresponding sub-class, before a non-preferred agent will be authorized.		
<b>ANTICHOLINERGICS</b>		
benztropine trihexyphenidyl		
<b>COMT INHIBITORS</b>		
entacapone	COMTAN (entacapone) TASMAR (tolcapone)	COMT Inhibitor agents will only be approved as add-on therapy to a levodopa-containing regimen for treatment of documented motor complications.
<b>DOPAMINE AGONISTS</b>		
pramipexole ropinirole	MIRAPEX (pramipexole) MIRAPEX ER (pramipexole)* NEUPRO (rotigotine) pramipexole ER REQUIP (ropinirole) REQUIP XL (ropinirole)* ropinirole ER	*Mirapex ER and Requip XL will be authorized for a diagnosis of Parkinsonism without a trial of preferred agents.
<b>OTHER ANTIPARKINSON'S AGENTS</b>		
amantadine <sup>AP</sup> APOKYN (apomorphine) bromocriptine carbidopa/levodopa levodopa/carbidopa/entacapone	AZILECT (rasagiline) carbidopa ELDEPRYL (selegiline) GOCOVRI ER (amantadine) INBRIJA (levodopa)	*Amantadine will not be authorized for the treatment or prophylaxis of influenza.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
selegiline	levodopa/carbidopa ODT LODOSYN (carbidopa) NOURIANZ (istradefylline) OSMOLEX ER (amantadine) PARCOPA (levodopa/carbidopa) PARLODEL (bromocriptine) rasagiline RYTARY (levodopa/carbidopa) SINEMET (levodopa/carbidopa) STALEVO (levodopa/carbidopa/entacapone) XADAGO (safinamide) ZELAPAR (selegiline)	
<b>ANTIPSORIATICS, TOPICAL</b> <b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of two (2) preferred unique chemical entities before they will be approved, unless one (1) of the exceptions on the PA form is present.		
TACLONEX OINT (calcipotriene/ betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol)	calcipotriene cream calcipotriene ointment calcipotriene solution calcipotriene/betamethasone ointment CALCITRENE (calcipotriene) calcitriol DOVONEX (calcipotriene) ENSTILAR (calcipotriene/betamethasone) SORILUX (calcipotriene) tazarotene cream (tazarotene)	
<b>ANTIPSYCHOTICS, ATYPICAL</b> <b>CLASS PA CRITERIA:</b> All antipsychotic agents require prior authorization for children up to eighteen (18) years of age. All PA requests for antipsychotics for children 6 years of age and younger will be reviewed by Medicaid's consultant psychiatrist.		
<p>Non-preferred agents require thirty (30) day trials of two (2) preferred agents, including the generic formulation of the requested agent (if available), before they will be approved unless one (1) of the exceptions on the PA form is present. All trials must be at the maximum recommended dose for the diagnosis provided before they would be considered a failure unless an adverse reaction is documented necessitating a change in therapy.</p> <p>Patients shall be grandfathered onto their existing therapy, provided the requested agent is being used according to the manufacturer label. Continuation of therapy for an off-label indication or non-standard dosage may be granted a thirty (30) day prior-authorization while the Medical Director reviews the request.</p>		
<b>SINGLE INGREDIENT</b>		
ABILIFY MAINTENA (aripiprazole) <sup>CL</sup> aripiprazole tablets	ABILIFY MYCITE (aripiprazole) ABILIFY TABLETS (aripiprazole)	<b>The following criteria exceptions apply to the specified products:</b>



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ARISTADA (aripiprazole) <sup>CL</sup> ARISTADA INITIO (aripiprazole) <sup>CL</sup> clozapine INVEGA SUSTENNA (paliperidone) <sup>CL</sup> INVEGA TRINZA (paliperidone)* <sup>CL</sup> olanzapine olanzapine ODT PERSERIS (risperidone) <sup>CL</sup> quetiapine ER quetiapine** AP for the 25 mg Tablet Only RISPERDAL CONSTA (risperidone) <sup>CL</sup> risperidone ODT risperidone solution, tablet ziprasidone ZYPREXA RELPREVV (olanzapine)	ADASUVE (loxapine) aripiprazole solution CAPLYTA (lumateperone) clozapine ODT CLOZARIL (clozapine) FANAPT (iloperidone) FAZACLO (clozapine) GEODON (ziprasidone) GEODON IM (ziprasidone) INVEGA ER (paliperidone) LATUDA (lurasidone)*** NUPLAZID (pimavanserin)**** olanzapine IM <sup>CL</sup> paliperidone ER REXULTI (brexipiprazole) RISPERDAL (risperidone) SAPHRIS (asenapine) SECUADO (asenapine) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) VERSACLOZ (clozapine) VRAYLAR (capripazine)***** VRAYLAR DOSE PAK (capripazine)***** ZYPREXA (olanzapine) ZYPREXA IM (olanzapine) <sup>CL</sup>	*Invega Trinza will be authorized after four months' treatment with Invega Sustenna  **Quetiapine 25 mg will be authorized: 1. For a diagnosis of schizophrenia <b>or</b> 2. For a diagnosis of bipolar disorder <b>or</b> 3. When prescribed concurrently with other strengths of Seroquel in order to achieve therapeutic treatment levels.  <b>Quetiapine 25 mg will not be authorized for use as a sedative hypnotic.</b>  *** LATUDA will be authorized for the indication of <u>Bipolar Depression</u> with documentation of the diagnosis. All other indications require class criteria to be followed.  ****Nuplazid may only be authorized for the treatment of Parkinson Disease Induced Psychosis after documented treatment failure with quetiapine.  ***** VRAYLAR may be authorized for the indication of <u>Bipolar Depression</u> only after failure of a 30-day trial of Latuda and a 30-day trial of either quetiapine OR a combination of olanzapine + fluoxetine. All other indications require class criteria to be followed.
<b>ATYPICAL ANTIPSYCHOTIC/SSRI COMBINATIONS</b>		
	olanzapine/fluoxetine SYMBYAX (olanzapine/fluoxetine)	
<b>ANTIRETROVIRALS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred drugs require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a preferred agent or combination of preferred agents. <b>NOTE:</b> Regimens consisting of preferred agents will result in no more than one additional unit per day over equivalent regimens composed of non-preferred agents. Patients already on a non-preferred regimen shall be grandfathered.		
<b>SINGLE TABLET REGIMENS</b>		
BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) COMPLERA (emtricitabine/rilpivirine/tenofovir) DELSTRIGO(doravirine/lamivudine/tenofovir df)	ATRIPLA (efavirenz/emtricitabine/tenofovir) DOVATO (dolutegravir/lamivudine) JULUCA (dolutegravir/rilpivirine) SYMTUZA	*Stribild requires medical reasoning beyond convenience or enhanced compliance as to why the medical need cannot be met with the the preferred agent Genvoya.



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir) ODEFSEY (emtricitabine/rilpivirine/tenofovir) SYMFI (efavirenz/lamivudine/tenofovir) SYMFI LO (efavirenz/lamivudine/tenofovir)	(darunavir/cobicistat/emtricitabine/tenofovir alafenamide) STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir)* TRIUMEQ (abacavir/lamivudine/dolutegravir)**	**Triumeq requires medical reasoning beyond convenience or enhanced compliance as to why the medical need cannot be met with the preferred agents Epzicom and Tivicay.
<b>INTEGRASE STRAND TRANSFER INHIBITORS</b>		
ISENTRESS (raltegravir potassium) TIVICAY (dolutegravir sodium) VITEKTA (elvitegravir)	ISENTRESS HD (raltegravir potassium)	
<b>NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)</b>		
abacavir sulfate tablet EMTRIVA (emtricitabine) EPIVIR SOLUTION (lamivudine) lamivudine tenofovir disoproxil fumarate VIREA ORAL POWDER (tenofovir disoproxil fumarate) ZIAGEN SOLUTION (abacavir sulfate) zidovudine	abacavir sulfate solution didanosine DR capsule EPIVIR TABLET (lamivudine) RETROVIR (zidovudine) stavudine VIDEX EC (didanosine) VIDEX SOLUTION (didanosine) VIREAD TABLETS (tenofovir disoproxil fumarate) ZERIT (stavudine) ZIAGEN TABLET (abacavir sulfate)	
<b>NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)</b>		
SUSTIVA (efavirenz)	EDURANT (rilpivirine) efavirenz INTELENCE (etravirine) nevirapine nevirapine ER PIFELTRO (doravirine) RESCRIPTOR (delavirdine mesylate) VIRAMUNE ER 24H (nevirapine) VIRAMUNE SUSPENSION (nevirapine)	
<b>PHARMACOENHANCER – CYTOCHROME P450 INHIBITOR</b>		
TYBOST (cobicistat)		
<b>PROTEASE INHIBITORS (PEPTIDIC)</b>		
atazanavir EVOTAZ (atazanavir/cobicistat) NORVIR (ritonavir)	CRIXIVAN (indinavir) fosamprenavir INVIRASE (saquinavir mesylate)	





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
REYATAZ POWDER PACK (atazanavir)	LEXIVA (fosamprenavir) REYATAZ CAPSULE (atazanavir) VIRACEPT (nelfinavir mesylate)	
<b>PROTEASE INHIBITORS (NON-PEPTIDIC)</b>		
PREZCOBIX (darunavir/cobicistat) PREZISTA (darunavir ethanolate)	APTIVUS (tipranavir)	
<b>ENTRY INHIBITORS – CCR5 CO-RECEPTOR ANTAGONISTS</b>		
<b>ENTRY INHIBITORS – FUSION INHIBITORS</b>		
<b>COMBINATION PRODUCTS - NRTIs</b>		
abacavir/lamivudine CIMDUO (lamivudine/tenofovir) lamivudine/zidovudine	abacavir/lamivudine/zidovudine COMBIVIR (lamivudine/zidovudine) EPZICOM (abacavir/lamivudine) <b>TEMIXYS (lamivudine/tenofovir)</b> TRIZIVIR (abacavir/lamivudine/zidovudine)	
<b>COMBINATION PRODUCTS – NUCLEOSIDE &amp; NUCLEOTIDE ANALOG RTIs</b>		
DESCOVY (emtricitabine/tenofovir)	TRUVADA (emtricitabine/tenofovir)*	*Truvada shall be treated as preferred when prescribed for PrEP in members assigned female at birth. Truvada may also be approved over Descovy where guidelines clearly indicate superiority over Descovy (documentation may be required to support the request for PA).
<b>COMBINATION PRODUCTS – PROTEASE INHIBITORS</b>		
KALETRA (lopinavir/ritonavir)	lopinavir/ritonavir	
<b>ANTIVIRALS, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five (5) day trials of each preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>ANTI HERPES</b>		
acyclovir valacyclovir	famciclovir FAMVIR (famciclovir) SITAVIG (acyclovir) VALTREX (valacyclovir) ZOVIRAX (acyclovir)	
<b>ANTI-INFLUENZA</b>		
oseltamivir RELENZA (zanamivir) TAMIFLU (oseltamivir)	FLUMADINE (rimantadine) rimantadine XOFLUZA (baloxavir)	<b>In addition to the Class Criteria:</b> The anti-influenza agents will be authorized only for a diagnosis of influenza.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>ANTIVIRALS, TOPICAL<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five (5) day trial of the preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
ABREVA (docosanol) ZOVIRAX CREAM (acyclovir) ZOVIRAX OINTMENT (acyclovir)	acyclovir ointment DENAVER (penciclovir)	
<b>BETA BLOCKERS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require fourteen (14) day trials of three (3) chemically distinct preferred agents, including the generic formulation of the requested non-preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>BETA BLOCKERS</b>		
acebutolol atenolol betaxolol bisoprolol CORGARD (nadolol) metoprolol metoprolol ER pindolol propranolol SORINE (sotalol) sotalol timolol	BETAPACE (sotalol) BYSTOLIC (nebivolol) HEMANGEOL (propranolol)* INDERAL LA (propranolol) INDERAL XL (propranolol) INNOPRAN XL (propranolol) KAPSPARGO SPRINKLE (metoprolol) KERLONE (betaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) nadolol propranolol ER** SECTRAL (acebutolol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)	*Hemangeol will be authorized for the treatment of proliferating infantile hemangioma requiring systemic therapy.  **Propranolol ER shall be authorized for patients with a diagnosis of migraines. Existing users will be grandfathered for use in migraine prophylaxis.
<b>BETA BLOCKER/DIURETIC COMBINATION DRUGS</b>		
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ propranolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol ER/HCTZ ER) LOPRESSOR HCT (metoprolol/HCTZ) metoprolol/HCTZ ER nadolol/bendroflumethiazide TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)	
<b>BETA- AND ALPHA-BLOCKERS</b>		
carvedilol labetalol	COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>BLADDER RELAXANT PREPARATIONS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each chemically distinct preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present		
GELNIQUE (oxybutynin) oxybutynin IR oxybutynin ER solifenacin TOVIAZ (fesoterodine)	DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN XL (oxybutynin) ENABLEX (darifenacin) flavoxate MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) SANCTURA (trospium) SANCTURA XR (trospium) tolterodine tolterodine ER trospium trospium ER VESICARE (solifenacin)	
<b>BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> See below for class criteria.		
<b>BISPHOSPHONATES</b>		
alendronate tablets ibandronate	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/ calcium) alendronate solution ATELVIA (risedronate) BINOSTO (alendronate) BONIVA (ibandronate) DIDRONEL (etidronate) etidronate FOSAMAX TABLETS (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) risedronate	Non-preferred agents require thirty (30) day trials of <b>each</b> preferred Bisphosphonate agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>OTHER BONE RESORPTION SUPPRESSION AND RELATED AGENTS</b>		
	calcitonin EVISTA (raloxifene)* FORTEO (teriparatide) FORTICAL (calcitonin) MIACALCIN (calcitonin) raloxifene*	Non-preferred agents require a thirty (30) day trial of a preferred Bisphosphonate agent before they will be approved, unless one (1) of the exceptions on the PA form is present.  *Raloxifene will be authorized for postmenopausal women with osteoporosis or at high risk for invasive breast cancer.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TYMLOS (abaloparatide)	
<b>BPH TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of at least two (2) chemically distinct preferred agents, including the generic formulation of the requested non-preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>5-ALPHA-REDUCTASE (5AR) INHIBITORS AND PDE-5 AGENTS</b>		
finasteride	AVODART (dutasteride) CIALIS 5 mg (tadalafil) dutasteride PROSCAR (finasteride)	
<b>ALPHA BLOCKERS</b>		
alfuzosin doxazosin tamsulosin terazosin	CARDURA (doxazosin) CARDURA XL (doxazosin) FLOMAX (tamsulosin) HYTRIN (terazosin) RAPAFLO (silodosin) silodosin UROXATRAL (alfuzosin)	
<b>5-ALPHA-REDUCTASE (5AR) INHIBITORS/ALPHA BLOCKER COMBINATION</b>		
	dutasteride/tamsulosin JALYN (dutasteride/tamsulosin)	<b>Substitute for Class Criteria:</b> Concurrent thirty (30) day trials of dutasteride and tamsulosin are required before the non-preferred agent will be authorized.
<b>BRONCHODILATORS, BETA AGONIST<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each chemically distinct preferred agent in their corresponding sub-class unless one (1) of the exceptions on the PA form is present.		
<b>INHALATION SOLUTION</b>		
albuterol	BROVANA (arformoterol) levalbuterol metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)*	*Xopenex Inhalation Solution will be authorized for twelve (12) months for a diagnosis of asthma or COPD for patients on concurrent asthma controller therapy (either oral or inhaled) with documentation of failure on a trial of albuterol or documented intolerance of albuterol, or for concurrent diagnosis of heart disease.
<b>INHALERS, LONG-ACTING</b>		
FORADIL (formoterol) SEREVENT (salmeterol)	ARCAPTA (indacaterol maleate) STRIVERDI RESPIMAT (olodaterol)	
<b>INHALERS, SHORT-ACTING</b>		
PROAIR HFA (albuterol) PROAIR RESPICLICK (albuterol)	albuterol HFA MAXAIR (pirbuterol) PROAIR DIGIHALER (albuterol)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	<b>PROVENTIL HFA (albuterol)</b> VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol)	
<b>ORAL</b>		
	albuterol ER albuterol IR metaproterenol VOSPIRE ER (albuterol) terbutaline	
<b>CALCIUM CHANNEL BLOCKERS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require fourteen (14) day trials of each preferred agent within the corresponding sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>LONG-ACTING</b>		
amlodipine diltiazem ER felodipine ER nifedipine ER verapamil ER	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD, LA (diltiazem) COVERA-HS (verapamil) diltiazem LA KATERZIA SUSPENSION (amlodipine)* MATZIM LA (diltiazem) nisoldipine NORVASC (amlodipine) PLENDIL (felodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine) TIAZAC (diltiazem) verapamil ER PM VERELAN/VERELAN PM (verapamil)	*Katerzia will be authorized for children who are 6-10 years of age who are unable to ingest solid dosage forms. Katerzia may also be authorized for older patients with clinical documentation indicating oral-motor difficulties or dysphagia.
<b>SHORT-ACTING</b>		
diltiazem verapamil	CALAN (verapamil) CARDIZEM (diltiazem) isradipine nicardipine nifedipine nimodipine NIMOTOP (nimodipine) NYMALIZE SOLUTION (nimodipine) PROCARDIA (nifedipine)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CEPHALOSPORINS AND RELATED ANTIBIOTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five (5) day trial of a preferred agent within the corresponding sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>BETA LACTAMS AND BETA LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS</b>		
amoxicillin/clavulanate IR	amoxicillin/clavulanate ER AUGMENTIN (amoxicillin/clavulanate) AUGMENTIN XR (amoxicillin/clavulanate) MOXATAG (amoxicillin)	
<b>CEPHALOSPORINS</b>		
cefaclor capsule cefadroxil capsule, tablet cefdinir cefuroxime tablet cephalexin capsule, suspension	CEDAX (ceftibuten) cefaclor suspension cefaclor ER tablet cefadroxil suspension cefprozime cefprozil ceftibuten capsule, suspension CEFTIN (cefuroxime) cefuroxime suspension cephalexin tablet DAXABIA (cephalexin) KEFLEX (cephalexin) OMNICEF (cefdinir) RANICLOR (cefaclor) SUPRAX (cefixime)	
<b>COPD AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a sixty (60) day trial of one preferred agent from the corresponding sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>ANTICHOLINERGIC<sup>AP</sup></b>		
ATROVENT HFA (ipratropium) ipratropium nebulizer solution SPIRIVA (tiotropium) SPIRIVA RESPIMAT (tiotropium) TUDORZA (aclidinium)	INCRUSE ELLIPTA (umeclidinium) LONHALA MAGNAIR (glycopyrrolate) SEEBRI NEOHALER (glycopyrrolate) YUPELRI SOLUTION (revefenacin)	
<b>ANTICHOLINERGIC-BETA AGONIST COMBINATIONS<sup>AP</sup></b>		
ANORO ELLIPTA (umeclidinium/vilanterol) albuterol/ipratropium nebulizer solution BEVESPI (glycopyrrolate/formoterol) COMBIVENT RESPIMAT (albuterol/ipratropium)	DUAKLIR PRESSAIR (aclidinium/formoterol)* DUONEB (albuterol/ipratropium) STIOLTO RESPIMAT (tiotropium/olodaterol)**	*In addition to the Class PA criteria, Duaklir Pressair requires sixty (60) day trials of each long acting preferred agent, as well as a 60-day trial of Stiolto Respimat.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
UTIBRON (indacaterol/glycopyrrolate)		**In addition to the Class PA criteria, Stiolto Respimat requires a sixty (60) day trial of a long acting preferred agent.
<b>ANTICHOLINERGIC-BETA AGONIST-GLUCOCORTICOID COMBINATIONS</b>		
	TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol)*	* Trelegly Ellipta may be prior authorized for patients currently established on the individual components for at least 30 days.
<b>PDE4 INHIBITOR</b>		
	DALIRESP (roflumilast)*	*Daliresp will be authorized if the following criteria are met: 1. Patient is forty (40) years of age or older <b>and</b> 2. Diagnosis of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and multiple exacerbations requiring systemic glucocorticoids in the preceding six (6) months <b>and</b> 3. Concurrent therapy with an inhaled corticosteroid and long-acting bronchodilator and evidence of compliance <b>and</b> 4. No evidence of moderate to severe liver impairment (Child-Pugh Class B or C) <b>and</b> 5. No concurrent use with strong cytochrome P450 inducers (rifampicin, phenobarbital, carbamazepine or phenytoin)
<b>CYTOKINE &amp; CAM ANTAGONISTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require ninety (90) day trials of both Humira and Enbrel unless one (1) of the exceptions on the PA form is present. For FDA-approved indications, an additional ninety (90) day trial of Cosentyx will also be required. <i>Patients stabilized for at least 6-months on their existing non-preferred regimen shall be grandfathered (provided the current therapy is for a labeled indication). All off-label requests require review by the Medical Director.</i>		
<b>ANTI-TNFs</b>		
ENBREL (etanercept)* HUMIRA (adalimumab)*	CIMZIA (certolizumab pegol) REMICADE (infliximab) RENFLEXIS (infliximab) SIMPONI subcutaneous (golimumab)	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>OTHERS</b>		
TALTZ (ixekizumab) XELJANZ (tofacitinib)**	ACTEMRA subcutaneous (tocilizumab) COSENTYX (secukinumab)* ENTYVIO (vedolizumab) ILARIS (canakinumab)	*Cosentyx will be authorized for treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis only after inadequate response to a ninety (90) day trial of one preferred agent.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ILUMYA (tildrakizumab) KEVZARA (sarilumab) KINERET (anakinra) OLUMIANT (baricitinib) ORENCIA subcutaneous (abatacept) OTEZLA (apremilast) RINVOQ ER (upadacitinib) SILIQ (brodalumab) SKYRIZI (risankizumab) STELARA subcutaneous (ustekinumab) TREMFYA (guselkumab) XELJANZ XR (tofacitinib)	<b>**Xeljanz is preferred for treatment of rheumatoid arthritis and ulcerative colitis only.</b>
<b>EPINEPHRINE, SELF-INJECTED</b>		
<b>CLASS PA CRITERIA:</b> A non-preferred agent may be authorized with documentation showing the patient's inability to follow the instructions, or the patient's failure to understand the training for the preferred agent(s).		
epinephrine (labeler 49502 only)	ADRENALIN (epinephrine) epinephrine (all labelers except 49502) EPIPEN (epinephrine) EPIPEN JR (epinephrine) SYMJEPI (epinephrine)	
<b>ERYTHROPOIESIS STIMULATING PROTEINS<sup>cl</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
EPOGEN (rHuEPO) RETACRIT (epoetin alfa)	ARANESP (darbepoetin) MIRCERA (methoxy PEG-epoetin) PROCRT (rHuEPO)	Erythropoiesis agents will be authorized if the following criteria are met: <ol style="list-style-type: none"> <li>Hemoglobin or Hematocrit less than 10/30 respectively. For renewal, hemoglobin or hematocrit levels greater than 12/36 will require dosage reduction or discontinuation. Exceptions will be considered on an individual basis after medical documentation is reviewed. (Laboratory values must be dated within six (6) weeks of request.) <b>and</b></li> <li>Transferrin saturation <math>\geq</math> 20%, ferritin levels <math>\geq</math> 100 mg/ml, or on concurrent therapeutic iron therapy. (Laboratory values must be dated within three (3) weeks of request. For re-authorization, transferrin saturation or ferritin levels are not required if the patient has been responsive to the erythropoietin agent <b>and</b></li> </ol>





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		3. For HIV-infected patients, endogenous serum erythropoietin level must be $\leq 500\text{mU/ml}$ to initiate therapy <b>and</b> 4. No evidence of untreated GI bleeding, hemolysis, or Vitamin B-12, iron or folate deficiency.
<b>FLUOROQUINOLONES (Oral)<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five (5) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
CIPRO SUSPENSION (ciprofloxacin) ciprofloxacin levofloxacin tablet	AVELOX (moxifloxacin) BAXDELA (delafloxacin) CIPRO TABLETS (ciprofloxacin) CIPRO XR (ciprofloxacin) ciprofloxacin ER ciprofloxacin suspension LEVAQUIN (levofloxacin) levofloxacin solution moxifloxacin NOROXIN (norfloxacin) ofloxacin	
<b>GLUCOCORTICIDS, INHALED<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each chemically unique preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>GLUCOCORTICIDS</b>		
ASMANEX TWISTHALER (mometasone) <b>budesonide nebulizer 0.5 mg/2 ml &amp; 0.25 mg/2 ml solution</b> FLOVENT DISKUS (fluticasone) FLOVENT HFA (fluticasone) PULMICORT FLEXHALER (budesonide)	AEROSPAN (flunisolide)** ALVESCO (ciclesonide) ARMONAIR RESPICLICK (fluticasone) ARNUITY ELLIPTA (fluticasone) ASMANEX HFA (mometasone) <b>PULMICORT NEBULIZER SOLUTION (budesonide)</b> <b>QVAR REDHALER (beclomethasone)</b>	*Pulmicort Respules are only preferred for children up to nine (9) years of age. For patients nine (9) and older, prior authorization is required and will be approved only for a diagnosis of severe nasal polyps.  **Aerospan will be authorized for children ages 6 through 11 years old without a trial of a preferred agent.
<b>GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS</b>		
<b>ADVAIR DISKUS (fluticasone/salmeterol)</b> ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) SYMBICORT (budesonide/formoterol)	AIRDUO RESPICLICK (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol) <b>fluticasone/salmeterol</b> WIXELA (fluticasone/salmeterol)	



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>GROWTH HORMONE<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three (3) month trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
GENOTROPIN (somatropin) NORDITROPIN (somatropin)	HUMATROPE (somatropin) INCRELEX (mecasermin) NUTROPIN AQ (somatropin) OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) ZOMACTON (somatropin) ZORBTIVE (somatropin)	Patients already on a non-preferred agent will receive authorization to continue therapy on that agent for the duration of the existing PA.
<b>H. PYLORI TREATMENT</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a trial of the combination of individual preferred components of the requested non-preferred agent and must be used at the recommended dosages, frequencies and duration of the non-preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
Please use individual components: preferred PPI (omeprazole or pantoprazole) amoxicillin tetracycline metronidazole clarithromycin bismuth PYLERA (bismuth/metronidazole/tetracycline)	HELIDAC (bismuth/metronidazole/tetracycline) lansoprazole/amoxicillin/clarithromycin OMECLAMOX-PAK (omeprazole/amoxicillin/clarithromycin) PREVPAC (lansoprazole/amoxicillin/clarithromycin) TALICIA (omeprazole/amoxicillin/rifabutin)	
<b>HEPATITIS B TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require ninety (90) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
BARACLUDGE SOLUTION (entecavir)* entecavir lamivudine HBV	adefovir BARACLUDGE TABLET (entecavir) EPIVIR HBV (lamivudine) HEPSERA (adefovir) VEMLIDY (tenofovir alafenamide fumarate)	*Baraclude <u>solution</u> will be authorized only for patients with documentation of dysphagia.
<b>HEPATITIS C TREATMENTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> For patients starting therapy in this class, preferred regimens may be found on the <a href="#">PA Criteria</a> page. Requests for non-preferred regimens require medical reasoning why a preferred regimen cannot be used.		
EPCLUSA (sofosbuvir/velpatasvir)* MAVYRET (pibrentasvir/glecaprevir)* ribavirin	COPEGUS (ribavirin) DAKLINZA (daclatasvir)* HARVONI (ledipasvir/sofosbuvir)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ZEPATIER (elbasvir/grazoprevir)*	ledipasvir/sofosbuvir* MODERIBA 400 mg, 600 mg MODERIBA DOSE PACK PEGASYS (pegylated interferon) PEG-INTRON (pegylated interferon) OLYSIO (simeprevir)* REBETOL (ribavirin) RIBASPHERE RIBAPAK (ribavirin) RIBASPHERE 400 mg, 600 mg (ribavirin) sofosbuvir/velpatasvir* SOVALDI (sofosbuvir)* TECHNIVIE (ombitasvir/paritaprevir/ritonavir)* VIEKIRA PAK (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* VIEKIRA XR (dasabuvir/ombitasvir/ paritaprevir/ritonavir)* VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)	
<b>HYPERPARATHYROID AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
paricalcitol capsule	cinacalcet doxercalciferol HECTOROL (doxercalciferol) paricalcitol injection RAYALDEE (calcifediol) SENSIPAR (cinacalcet) ZEMPLAR (paricalcitol)	
<b>HYPOGLYCEMICS, BIGUANIDES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a ninety (90) day trial of a preferred agent of similar duration before they will be approved, unless one (1) of the exceptions on the PA form is present.		
metformin metformin ER (generic Glucophage XR)	FORTAMET (metformin ER) GLUCOPHAGE (metformin) GLUCOPHAGE XR (metformin ER) GLUMETZA (metformin ER)* metformin ER (generic Glumetza & Fortamet) RIOMET (metformin)	*Glumetza will be approved only after a 30-day trial of Fortamet.
<b>HYPOGLYCEMICS, DPP-4 INHIBITORS</b>		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CLASS PA CRITERIA:</b> Non-preferred agents are available only on appeal.		
<b>NOTE:</b> DPP-4 inhibitors will NOT be approved in combination with a GLP-1 agonist.		
JANUMET (sitagliptin/metformin) JANUMET XR (sitagliptin/metformin) JANUVIA (sitagliptin) JENTADUETO (linagliptin/metformin) TRADJENTA (linagliptin)	alogliptin alogliptin/metformin alogliptin/pioglitazone JENTADUETO XR (linagliptin/metformin) KAZANO (alogliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin) NESINA (alogliptin) ONGLYZA (saxagliptin) OSENI (alogliptin/pioglitazone)	
<b>HYPOGLYCEMICS, GLP-1 AGONISTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be approved (in 6-month intervals) if ALL of the following criteria has been met:		
<ol style="list-style-type: none"> <li>1) Current A1C must be submitted. Agents in this class will not be approved for patients with a starting A1C of less than (&lt;) 7%.</li> <li>2) Documentation demonstrating 90 days of compliance <u>on all current diabetic therapies</u> is provided.</li> <li>3) Documentation demonstrating treatment failure with all unique preferred agents in the same class.</li> </ol>		
Re-authorizations will require documentation of <u>continued</u> compliance on all diabetic therapies and A1C levels must reach goal, (either an A1C of ≤8%, or demonstrated continued improvement).		
<b>NOTE:</b> GLP-1 agents will NOT be approved in combination with a DPP-4 inhibitor.		
OZEMPIC (semaglutide) TRULICITY (dulaglutide) VICTOZA (liraglutide)	ADLYXIN (lixisenatide) BYDUREON (exenatide) BYETTA (exenatide) BYDUREON BCISE (exenatide) RYBELSUS (semaglutide) TANZEUM (albiglutide)	
<b>HYPOGLYCEMICS, INSULIN AND RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a ninety (90) day trial of a pharmacokinetically similar agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
APIDRA (insulin glisine) <sup>AP*</sup> FIASP (insulin aspart)	ADMELOG (insulin lispro) AFREZZA (insulin) <sup>CL</sup>	*Apidra will be authorized if the following criteria are met: 1. Patient is four (4) years of age or older; <b>and</b>



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
HUMALOG (insulin lispro) HUMALOG JR KWIKPEN (insulin lispro) HUMALOG KWIKPEN U-100 (insulin lispro) HUMALOG MIX PENS (insulin lispro/lispro protamine) HUMALOG MIX VIALS (insulin lispro/lispro protamine) HUMULIN N VIAL (insulin) HUMULIN R U-500 VIAL (insulin) HUMULIN R U-500 KWIKPEN (insulin) LANTUS (insulin glargine) LEVEMIR (insulin detemir) NOVOLOG (insulin aspart) NOVOLOG MIX (insulin aspart/aspart protamine) TRESIBA (insulin degludec) TRESIBA FLEXTOUCH (insulin degludec)	BASAGLAR (insulin glargine) HUMULIN PENS (insulin) HUMULIN R VIAL (insulin) HUMULIN 70/30 (insulin) insulin aspart insulin aspart/aspart protamine insulin lispro NOVOLIN (insulin) SOLIQUA (insulin glargine/lixisenatide)** TOUJEO SOLOSTAR (insulin glargine)*** XULTOPHY (insulin degludec/liraglutide)**	<ol style="list-style-type: none"> <li>2. Patient is currently on a regimen including a longer acting or basal insulin, <b>and</b></li> <li>3. Patient has had a trial of a similar preferred agent, Novolog or Humalog, with documentation that the desired results were not achieved..</li> </ol> <p>** Non-preferred insulin combination products require that the patient must already be established on the individual agents at doses not exceeding the maximum dose achievable with the combination product, and require medical reasoning beyond convenience or enhanced compliance as to why the clinical need cannot be met with a combination of preferred single-ingredient agents.</p> <p>***Toujeo Solostar and Toujeo Max Solostar may be approved only for:</p> <ol style="list-style-type: none"> <li>1.) Patients who require once-daily doses of at least 60 units of long-acting insulin and have demonstrated at least a 6-month history of compliance on preferred long-acting insulin and who continue to have regular incidents of hypoglycemia.</li> </ol> <p><b>OR</b></p> <ol style="list-style-type: none"> <li>2.) Patients who currently require over 200 units per day of long-acting insulin.</li> </ol>
<b>HYPOGLYCEMICS, MEGLITINIDES</b>		
<b>CLASS PA CRITERIA: Non-preferred agents are available only on appeal.</b>		
<b>MEGLITINIDES</b>		
nateglinide repaglinide	PRANDIN (repaglinide) STARLIX (nateglinide)	
<b>MEGLITINIDE COMBINATIONS</b>		
	PRANDIMET (repaglinide/metformin) repaglinide/metformin	
<b>HYPOGLYCEMICS, MISCELLANEOUS AGENTS</b>		
<b>CLASS PA CRITERIA: Welchol will be authorized for add-on therapy for type 2 diabetes when there is a previous history of a thirty (30) day trial of an oral diabetic agent.</b>		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
WELCHOL (colesevelam) <sup>AP</sup>	SYMLIN (pramlintide)*	*Symlin will be authorized with a history of bolus insulin utilization in the past ninety (90) days with no gaps in insulin therapy greater than thirty (30) days.
<b>HYPOGLYCEMICS, SGLT2 INHIBITORS<sup>CL</sup></b> <b>CLASS PA CRITERIA:</b> Non-preferred agents will only be approved (in 6-month intervals) if ALL of the following criteria has been met: <ol style="list-style-type: none"> <li>1) Current A1C must be submitted. Agents in this class will not be approved for patients with a starting A1C of less than (&lt;) 7%.</li> <li>2) Documentation demonstrating 90 days of compliance <u>on all current diabetic therapies</u> is provided.</li> <li>3) Documentation demonstrating treatment failure with all unique preferred agents in the same class.</li> </ol> <p>Re-authorizations will require documentation of <u>continued</u> compliance on all diabetic therapies and A1C levels must reach goal, (either an A1C of ≤8%, or demonstrated continued improvement).</p>		
<b>SGLT2 INHIBITORS</b>		
FARXIGA (dapagliflozin) INVOKANA (canagliflozin) JARDIANCE (empagliflozin)	STEGLATRO (ertugliflozin)	
<b>SGLT2 COMBINATIONS</b>		
INVOKAMET (canagliflozin/metformin) SYNJARDY (empagliflozin/metformin)	GLYXAMBI (empagliflozin/linagliptin) INVOKAMET XR (canagliflozin/metformin) SEGLUROMET (ertugliflozin/metformin) STEGLUJAN (ertugliflozin/sitagliptin) SYNJARDY XR (empagliflozin/metformin) <b>TRIJARDY XR</b> <b>(empagliflozin/linagliptin/metformin)</b> QTERN (dapagliflozin/saxagliptin) XIGDUO XR (dapagliflozin/metformin)	
<b>HYPOGLYCEMICS, TZD</b> <b>CLASS PA CRITERIA:</b> Non-preferred agents are available only on appeal.		
<b>THIAZOLIDINEDIONES</b>		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
pioglitazone	ACTOS (pioglitazone) AVANDIA (rosiglitazone)	
<b>TZD COMBINATIONS</b>		
	ACTOPLUS MET (pioglitazone/ metformin) ACTOPLUS MET XR (pioglitazone/ metformin) AVANDARYL (rosiglitazone/glimepiride) DUETACT (pioglitazone/glimepiride) pioglitazone/glimepiride pioglitazone/ metformin	Patients are required to use the components of Actoplus Met and Duetact separately. Exceptions will be handled on a case-by-case basis.
<b>IMMUNOMODULATORS, ATOPIC DERMATITIS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require 30-day trial of a medium to high potency topical corticosteroid <b>AND all</b> preferred agents in this class unless one (1) of the exceptions on the PA form is present. Requirement for topical corticosteroids may be excluded with involvement of sensitive areas such as the face and skin folds.		
pimecrolimus cream (labeler 68682 only) PROTOPIC (tacrolimus)	DUPIXENT (dupilumab)** ELIDEL (pimecrolimus) EUCRISA (crisaborole) <sup>AP*</sup> pimecrolimus cream tacrolimus ointment	*Eucrisa requires a 30-day trial of Elidel <b>OR</b> a medium to high potency corticosteroid unless contraindicated.  **Full PA criteria for Dupixent may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink
<b>IMMUNOMODULATORS, GENITAL WARTS &amp; ACTINIC KERATOSIS AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
CONDYLOX GEL (podofilox) EFUDEX (fluorouracil) imiquimod	ALDARA (imiquimod) CARAC (fluorouracil) diclofenac 3% gel fluorouracil 0.5% cream fluorouracil 5% cream podofilox SOLARAZE (diclofenac) TOLAK (fluorouracil 4% cream) VEREGEN (sinecatechins) ZYCLARA (imiquimod)*	*Zyclara will be authorized for a diagnosis of actinic keratosis.
<b>IMMUNOSUPPRESSIVES, ORAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a fourteen (14) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
azathioprine cyclosporine cyclosporine, modified mycophenolate mofetil sirolimus tacrolimus capsule	ASTAGRAF XL (tacrolimus) AZASAN (azathioprine) CELLCEPT (mycophenolate mofetil) ENVARBUS XR (tacrolimus) IMURAN (azathioprine) mycophenolic acid mycophenolic mofetil suspension MYFORTIC (mycophenolic acid) NEORAL (cyclosporine, modified) PROGRAF (tacrolimus) RAPAMUNE (sirolimus) SANDIMMUNE (cyclosporine) ZORTRESS (everolimus)	
<b>INTRANASAL RHINITIS AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual sub-class criteria.		
<b>ANTICHOLINERGICS</b>		
ipratropium	ATROVENT (ipratropium)	Non-preferred agents require thirty (30) day trials of one (1) preferred nasal anti-cholinergic agent, <b>AND</b> one (1) preferred antihistamine <b>AND</b> one (1) preferred intranasal corticosteroid agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>ANTIHISTAMINES</b>		
azelastine	ASTEPRO (azelastine) olopatadine PATANASE (olopatadine)	Non-preferred agents require thirty (30) day trials of one (1) preferred antihistamine <b>AND</b> one (1) preferred intranasal corticosteroid before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>COMBINATIONS</b>		
	DYMISTA (azelastine / fluticasone)	Dymista requires a concurrent thirty (30) day trial of each preferred component before it will be approved, unless one (1) of the exceptions on the PA form is present.
<b>CORTICOSTEROIDS</b>		
fluticasone propionate OMNARIS (ciclesonide) QNASL HFA (beclomethasone) ZETONNA (ciclesonide)	BECONASE AQ (beclomethasone) budesonide flunisolide mometasone NASACORT AQ (triamcinolone) NASONEX (mometasone) triamcinolone VERAMYST (fluticasone furoate)	Non-preferred agents require thirty (30) day trials of each preferred agent in this sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME/SELECTED GI AGENTS <sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> All agents are approvable only for patients age eighteen (18) and older. <b>See below for additional sub-class criteria.</b>		
<b>CONSTIPATION</b>		
AMITIZA (lubiprostone) MOVANTIK (naloxegol)	<b>LINZESS (linaclotide)</b> MOTEGRITY (prucalopride) RELISTOR INJECTION (methylnaltrexone) RELISTOR TABLET (methylnaltrexone) SYMPROIC (naldemedine) TRULANCE (plecanatide) <b>ZELNORM (tegaserod maleate)</b>	<p>All agents in this subclass require documentation of the current diagnosis and evidence that the patient has failed to find relief with dietary modification and a fourteen (14) day trial of an osmotic laxative.</p> <p>No agent shall be approved to treat opioid induced constipation (OIC) without evidence of at least 90-days of opioid use preceding the request. Continuation of coverage shall be granted with evidence of continuous and concurrent opioid use.</p> <p><b>Agents may be authorized only for their FDA-approved labeled indication. The following agent-specific criteria shall also apply:</b></p> <p><b>Motegrity</b> requires a 30-day trial of both Amitiza and Linzess. <b>Relistor</b> and <b>Symproic</b> are indicated for OIC and require thirty (30) day trials of both Movantik and Amitiza. <b>Trulance</b> requires thirty (30) day trials of both Amitiza and Linzess, however for the indication of IBS-C in <u>males</u>, a trial of Amitiza is not required.</p>
<b>DIARRHEA</b>		
	alosetron MYTESI (crofelemer) LOTRONEX (alosetron) VIBERZI (eluxadoline)	Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>LAXATIVES AND CATHARTICS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present		
COLYTE GOLYTELY	<b>CLENPIQ (sodium picosulfate, magnesium oxide, citric acid)</b>	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
NULYTELY peg 3350	HALFLYTELY-BISACODYL KIT MOVIPREP OSMOPREP PREPOPIK SUPREP	
<b>LEUKOTRIENE MODIFIERS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
montelukast zafirlukast	ACCOLATE (zafirlukast) SINGULAIR (montelukast) zileuton ZYFLO (zileuton)	
<b>LIPOTROPICS, OTHER (Non-statins)</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a twelve (12) week trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>BILE ACID SEQUESTRANTS<sup>AP</sup></b>		
cholestyramine colestipol tablets	COLESTID (colestipol) colestipol granules KYNAMRO (mipomersen)* QUESTRAN (cholestyramine) WELCHOL (colesevelam)**	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.  **Welchol will be authorized for add-on therapy for type 2 diabetes when there is a previous history of a thirty (30) day trial of an oral agent (metformin, sulfonylurea or thiazolidinedione (TZD)). See HYPOGLYCEMICS, MISCELLANEOUS.
<b>CHOLESTEROL ABSORPTION INHIBITORS</b>		
ezetimibe	ZETIA (ezetimibe)	
<b>FATTY ACIDS<sup>CL</sup></b>		
omega-3 acid ethyl esters VASCEPA (icosapent ethyl)	LOVAZA (omega-3-acid ethyl esters)	<sup>CL</sup> All agents in this subclass require a prior authorization and an initial triglyceride level $\geq$ 500 mg/dL. Additionally, Vascepa may be approved if the following criteria is met: <ol style="list-style-type: none"> <li>1. The patient has an initial triglyceride level of <math>\geq</math> 150 mg/dL prior to start of therapy; AND</li> <li>2. The patient has established cardiovascular disease or diabetes; AND</li> <li>3. The patient is concomitantly receiving a statin.</li> </ol>
<b>FIBRIC ACID DERIVATIVES<sup>AP</sup></b>		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
fenofibrate 54 and 160 mg fenofibrate micronized 67mg, 134mg & 200mg fenofibrate nanocrystallized 48 mg, 145 mg gemfibrozil	ANTARA (fenofibrate) FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) fenofibrate 40 mg tablet fenofibrate 150 mg capsules fenofibrate 43, 50, 120 and 130 mg fenofibric acid LIPOFEN (fenofibrate) LOFIBRA (fenofibrate) LOPID (gemfibrozil) TRICOR (fenofibrate nanocrystallized) TRIGLIDE (fenofibrate) TRILIPIX (fenofibric acid)	
<b>MTP INHIBITORS</b>		
	JUXTAPID (lomitapide)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>NIACIN</b>		
niacin niacin ER (OTC) NIACOR (niacin) NIASPAN (niacin)	niacin ER (Rx)	
<b>PCSK-9 INHIBITORS/BEMPEDOIC ACID</b>		
	PRALUENT (alirocumab)* REPATHA (evolocumab)* NEXLETOL (bempedoic acid)* NEXLIZET (bempedoic acid/ezetimibe)*	*Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>LIPOTROPICS, STATINS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual sub-class criteria.		
<b>STATINS</b>		
atorvastatin lovastatin pravastatin rosuvastatin simvastatin*	ALTOPREV (lovastatin) CRESTOR (rosuvastatin) EZALLOR (rosuvastatin) <sup>NR</sup> EZALLOR SPRINKLE (rosuvastatin)* fluvastatin fluvastatin ER LESCOL (fluvastatin) LESCOL XL (fluvastatin) LIPITOR (atorvastatin)	Non-preferred agents require twelve (12) week trials of two (2) preferred agents, including the generic formulation of the requested non-preferred agent, before they will be approved, unless one (1) of the exceptions on the PA form is present.  *Ezallor SPRINKLE will only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LIVALO (pitavastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin)** ZYPITAMAG (pitavastatin)	**Zocor/simvastatin 80mg tablets will require a clinical PA.
<b>STATIN COMBINATIONS</b>		
	ADVICOR (lovastatin/niacin) amlodipine/atorvastatin CADUET (atorvastatin/amlodipine) ezetimibe/simvastatin LIPTRUZET (atorvastatin/ezetimibe) SIMCOR (simvastatin/niacin ER) VYTORIN (simvastatin/ezetimibe)*	Non-preferred agents require thirty (30) day concurrent trials of the corresponding preferred single agents before they will be approved, unless one (1) of the exceptions on the PA form is present.  *Vytorin will be authorized only after an insufficient response to a twelve (12) week trial of the maximum tolerable dose of atorvastatin or rosuvastatin, unless one (1) of the exceptions on the PA form is present.  Vytorin 80/10mg tablets will require a clinical PA.
<b>MABS, ANTI-IL/IgE</b>		
<b>CLASS PA CRITERIA:</b> Full PA Criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.		
XOLAIR (omalizumab)	DUPIXENT (dupilumab) FASENRA (benralizumab) FASENRA PEN (benralizumab) NUCALA SYRINGE/VIAL (mepolizumab) NUCALA AUTO INJECTOR (mepolizumab)	
<b>MACROLIDES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a five (5) day trial of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
azithromycin erythromycin base	<b>MACROLIDES</b> BIAXIN (clarithromycin) clarithromycin tablets clarithromycin ER clarithromycin suspension E.E.S. (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED (erythromycin ethylsuccinate) ERY-TAB (erythromycin) ERYTHROCIN (erythromycin stearate) erythromycin estolate	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)	
<b>MULTIPLE SCLEROSIS AGENTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> All agents require a prior authorization and documented diagnosis of multiple sclerosis. Preferred oral agents require a ninety (90) day trial of any preferred injectable agent. Non-preferred agents require ninety (90) day trials of <u>each</u> chemically unique preferred agent (in the same sub-class) before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>INTERFERONS<sup>AP</sup></b>		
AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a)	EXTAVIA KIT (interferon beta-1b) EXTAVIA VIAL (interferon beta-1b) PLEGRIDY (peginterferon beta-1a)	
<b>NON-INTERFERONS</b>		
AUBAGIO (teriflunomide)** dalfampridine ER* COPAXONE 20 mg (glatiramer) GILENYA (fingolimod)	AMPYRA (dalfampridine)* COPAXONE 40 mg (glatiramer)** glatiramer GLATOPA (glatiramer) MAYZENT (siponimod)**** MAVENCLAD (cladribine) TECFIDERA (dimethyl fumarate)***** VUMERITY (diroximel) ZINBRYTA (daclizumab)	<b>In addition to class PA criteria, the following conditions and criteria may also apply:</b>  *Ampyra and dalfampridine ER require the following additional criteria to be met: <ol style="list-style-type: none"> <li>1. Diagnosis of multiple sclerosis <b>and</b></li> <li>2. No history of seizures <b>and</b></li> <li>3. No evidence of moderate or severe renal impairment.</li> </ol> **Aubagio requires the following additional criteria to be met: <ol style="list-style-type: none"> <li>1. Diagnosis of relapsing multiple sclerosis <b>and</b></li> <li>2. Measurement of transaminase and bilirubin levels within the (6) months before initiation of therapy and ALT levels at least monthly for six (6) months after initiation of therapy <b>and</b></li> <li>3. Complete blood cell count (CBC) within six (6) months before initiation of therapy <b>and</b></li> <li>4. Female patients must have a negative pregnancy test before initiation of therapy and be established on a reliable method of contraception if appropriate <b>and</b></li> <li>5. Patient is between eighteen (18) up to sixty-five (65) years of age <b>and</b></li> <li>6. Negative tuberculin skin test before initiation of therapy</li> </ol> ***Copaxone 40mg will only be authorized for documented



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		injection site issues.  ****Mayzent may be authorized with no additional requirement beyond the diagnosis for patients with documented <u>secondary progressive MS</u> .  ****Tecfidera requires the following additional criteria to be met: 1. Diagnosis of relapsing multiple sclerosis <b>and</b> 2. Complete blood count (CBC) within six (6) months of initiation of therapy and six (6) months after initiation <b>and</b> 3. Complete blood count (CBC) annually during therapy.
<b>NEUROPATHIC PAIN</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent in the corresponding dosage form (oral or topical) before they will be approved, unless one (1) of the exceptions on the PA form is present.		
capsaicin OTC duloxetine gabapentin lidocaine patch pregabalin capsule <b>ZTLIDO PATCH (lidocaine)</b>	CYMBALTA (duloxetine) DRIZALMA SPRINKLE (duloxetine)* GRALISE (gabapentin)** HORIZANT (gabapentin) IRENKA (duloxetine) LIDODERM (lidocaine) LYRICA CR (pregabalin)*** LYRICA SOLUTION (pregabalin)*** NEURONTIN (gabapentin) <sup>AP</sup> QUTENZA (capsaicin) SAVELLA (milnacipran)**** LYRICA CAPSULE (pregabalin)	*Drizalma SPRINKLE will only be authorized for those who are unable to ingest solid dosage forms due to documented oral-motor difficulties or dysphagia.  **Gralise will be authorized only if the following criteria are met: 1. Diagnosis of post herpetic neuralgia <b>and</b> 2. Trial of a tricyclic antidepressant for a least thirty (30) days <b>and</b> 3. 90-day trial of gabapentin immediate release formulation (positive response without adequate duration) <b>and</b> 4. Request is for once daily dosing with 1800 mg maximum daily dosage.  ***Lyrica CR and Lyrica Solution require medical reasoning beyond convenience as to why the need cannot be met using preferred pregabalin capsules.  ****Savella will be authorized for a diagnosis of fibromyalgia only after a 90-day trial of one preferred agent



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>NSAIDS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for sub-class PA criteria.		
<b>NON-SELECTIVE</b>		
diclofenac (IR, SR) flurbiprofen ibuprofen (Rx and OTC) INDOCIN SUSPENSION (indomethacin) indomethacin ketoprofen ketorolac meloxicam tablet nabumetone naproxen sodium tablet naproxen sodium DS tablet naproxen suspension EC-naproxen DR tablet piroxicam sulindac	CATAFLAM (diclofenac) CLINORIL (sulindac) DAYPRO (oxaprozin) diflunisal DUEXIS (famotidine/ibuprofen) etodolac IR etodolac SR FELDENE (piroxicam) fenoprofen INDOCIN SUPPOSITORIES (indomethacin) indomethacin ER ketoprofen ER meclofenamate mefenamic acid meloxicam suspension MOBIC TABLET (meloxicam) NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) naproxen CR oxaprozin PONSTEL (meclofenamate) RELAFEN DS (nabumetone) SPRIX (ketorolac) TIVORBEX (indomethacin) tolmetin VIVLODEX (meloxicam) VOLTAREN (diclofenac) ZIPSOR (diclofenac potassium) ZORVOLEX (diclofenac)	Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>NSAID/GI PROTECTANT COMBINATIONS</b>		
	ARTHROTEC (diclofenac/misoprostol) diclofenac/misoprostol VIMOVO (naproxen/esomeprazole)	Non-preferred agents are only available on appeal and require medical reasoning beyond convenience as to why the need cannot be met with the combination of preferred single agents.
<b>COX-II SELECTIVE</b>		



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**

This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	CELEBREX (celecoxib) celecoxib	COX-II Selective agents require thirty (30) day trials of each preferred Non-Selective Oral NSAID, <b>UNLESS</b> the following criteria are met:  Patient has a history or risk of a serious GI complication; <b>OR</b> Agent is requested for treatment of a chronic condition <b>and</b> 1. Patient is seventy (70) years of age or older, <b>or</b> 2. Patient is currently on anticoagulation therapy.
<b>TOPICAL</b>		
FLECTOR PATCH (diclofenac)* VOLTAREN GEL (diclofenac)**	diclofenac gel diclofenac solution PENNSAID (diclofenac)	*Flector patches are limited to two per day.  **Voltaren Gel will be limited to 100 grams per month.  Non-preferred agents require a thirty (30) day trial of the preferred Topical agent and thirty (30) day trials of each preferred oral NSAID before they will be approved, unless one(1) of the exceptions on the PA form is present.
<b>OPHTHALMIC ANTIBIOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three (3) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
bacitracin/polymyxin ointment ciprofloxacin* erythromycin gentamicin levofloxacin* MOXEZA (moxifloxacin) neomycin/bacitracin/polymyxin ofloxacin* polymyxin/trimethoprim tobramycin TOBEX OINT (tobramycin)	AZASITE (azithromycin) bacitracin BLEPH-10 (sulfacetamide) BESIVANCE (besifloxacin)* CILOXAN (ciprofloxacin) GARAMYCIN (gentamicin) gatifloxacin ILOTYCIN (erythromycin) moxifloxacin** NATACYN (natamycin) neomycin/polymyxin/gramicidin NEOSPORIN (neomycin/polymyxin/gramicidin) OCUFLOX (ofloxacin) POLYTRIM (polymyxin/trimethoprim) sulfacetamide drops sulfacetamide ointment TOBEX (tobramycin) VIGAMOX (moxifloxacin)** ZYMAR (gatifloxacin) ZYMAXID (gatifloxacin)	*Prior authorization of any fluoroquinolone agent requires three (3) day trials of all other preferred agents unless definitive laboratory cultures exist indicating the need to use a fluoroquinolone.





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require three (3) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
neomycin/polymyxin/dexamethasone sulfacetamide/prednisolone TOBRADEX OINTMENT (tobramycin/ dexamethasone) TOBRADEX SUSPENSION (tobramycin/ dexamethasone) ZYLET (loteprednol/tobramycin)	BLEPHAMIDE (prednisolone/sulfacetamide) BLEPHAMIDE S.O.P. (prednisolone/ sulfacetamide) MAXITROL ointment (neomycin/polymyxin/ dexamethasone) MAXITROL suspension (neomycin/polymyxin/ dexamethasone) neomycin/bacitracin/polymyxin/ hydrocortisone neomycin/polymyxin/hydrocortisone PRED-G (prednisolone/gentamicin) TOBRADEX ST (tobramycin/ dexamethasone) tobramycin/dexamethasone suspension	
<b>OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of three (3) preferred chemically unique agents before they will be approved, unless one (1) of the exceptions on the PA form is present.		
ALAWAY (ketotifen) ALREX (loteprednol) BEPREVE (bepotastine) cromolyn ketotifen LASTACAFT (alcaftadine) olopatadine 0.1% (Generic PATANOL labeler 61314 only) ZADITOR OTC (ketotifen)	ALAMAST (pemirolast) ALOCRIL (nedocromil) ALOMIDE (Iodoxamide) azelastine CROLOM (cromolyn) ELESTAT (epinastine) EMADINE (emedastine) Epinastine <b>LUMIFY (brimonidine)</b> olopatadine 0.1% (all formulations except Generic PATANOL labeler 61314) olopatadine 0.2% (all labelers) OPTICROM (cromolyn) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) PAZEO (olopatadine) <b>ZERVATE (cetirizine)</b>	
<b>OPHTHALMICS, ANTI-INFLAMMATORIES- IMMUNOMODULATORS<sup>CL</sup></b>		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>CLASS PA CRITERIA:</b> All agents require a prior authorization. Non-preferred agents require a 60-day trial of the preferred agent(s).		
RESTASIS (cyclosporine)	CEQUA (cyclosporine) RESTASIS MULTIDOSE (cyclosporine)* XIIDRA (lifitegrast)*	<p><b>*Restasis Multidose</b> is approvable only on appeal and requires medical reasoning as to why the clinical need can not be met with the preferred product (Restasis).</p> <p><b>All agents must meet the following prior-authorization criteria:</b></p> <ol style="list-style-type: none"> <li>1.) Patient must be sixteen (16) years of age or greater; <b>AND</b></li> <li>2.) Prior Authorization must be requested by an ophthalmologist or optometrist; <b>AND</b></li> <li>3.) Clinically diagnosed tear deficiency due to ocular inflammation in patients with keratoconjunctivitis sicca or dry eye syndrome (also known as dry eye); <b>AND</b></li> <li>4.) Patient must have a functioning lacrimal gland; <b>AND</b></li> <li>5.) Patient using artificial tears at least four (4) times a day over the last thirty (30) days; <b>AND</b></li> </ol> Patient must not have an active ocular infection
<b>OPHTHALMICS, ANTI-INFLAMMATORIES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five (5) day trials of at least two (2) preferred agents before they will be approved, unless one (1) of the exceptions on the PA form is present. Trials must include at least one agent with the same mechanism of action as the requested non-preferred agent.		
dexamethasone diclofenac DUREZOL (difluprednate) fluorometholone FML FORTE (fluorometholone) FML S.O.P. (fluorometholone) ketorolac LOTEMAX DROPS, OINTMENT (loteprednol) MAXIDEX (dexamethasone) NEVANAC (nepafenac) PRED MILD (prednisolone) prednisolone acetate prednisolone sodium phosphate	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac tromethamine) BROMDAY (bromfenac) bromfenac BROMSITE (bromfenac) FLAREX (fluorometholone) flurbiprofen FML (fluorometholone) ILEVRO (nepafenac) INVELTYS (loteprednol) LOTEMAX GEL (loteprednol) OMNIPRED (prednisolone) OZURDEX (dexamethasone) PRED FORTE (prednisolone) PROLENSA (bromfenac) RETISERT (fluocinolone)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TRIESENCE (triamcinolone) VEXOL (rimexolone) XIBROM (bromfenac)	
<b>OPHTHALMICS, GLAUCOMA AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents will only be authorized if there is an allergy to all preferred agents in the corresponding sub-class.		
<b>COMBINATION AGENTS</b>		
COMBIGAN (brimonidine/timolol) dorzolamide/timolol SIMBRINZA (brinzolamide/brimonidine)	COSOPT (dorzolamide/timolol) COSOPT PF (dorzolamide/timolol)	
<b>BETA BLOCKERS</b>		
BETOPTIC S (betaxolol) carteolol levobunolol timolol drops	BETAGAN (levobunolol) betaxolol ISTALOL (timolol) OPTIPRANOLOL (metipranolol) timolol gel TIMOPTIC (timolol)	
<b>CARBONIC ANHYDRASE INHIBITORS</b>		
AZOPT (brinzolamide) orzolamide	TRUSOPT (dorzolamide)	
<b>PARASYMPATHOMIMETICS</b>		
PHOSPHOLINE IODIDE (echothiophate iodide)	pilocarpine	
<b>PROSTAGLANDIN ANALOGS</b>		
latanoprost TRAVATAN-Z (travoprost)	bimatoprost LUMIGAN (bimatoprost) travoprost VYZULTA (latanoprostene)* XALATAN (latanoprost) XELPROS (latanoprost) ZIOPTAN (tafluprost)	*Vyzulta – prior authorization requires failure on a 3-month trial of at least one preferred prostaglandin eye drop used in combination with an agent from another subclass.
<b>RHO-KINASE INHIBITORS</b>		
RHOPRESSA (netarsudil) ROCKLATAN (netarsudil/latanoprost)		
<b>SYMPATHOMIMETICS</b>		
brimonidine 0.2%	ALPHAGAN P 0.1% Solution (brimonidine) ALPHAGAN P 0.15% Solution (brimonidine) apraclonidine brimonidine 0.15% IOPIDINE (apraclonidine)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>OPIATE DEPENDENCE TREATMENTS</b>		
<b>CLASS PA CRITERIA:</b> Bunavail and Zubsolv may only be approved with a documented intolerance or allergy to Suboxone strips AND buprenorphine/naloxone tablets.  WV Medicaid's buprenorphine coverage policy may be viewed by clicking on the following hyperlink: <a href="#">Buprenorphine Coverage Policy and Related Forms</a>		
buprenorphine/naloxone tablets* naloxone NARCAN NASAL SPRAY (naloxone) SUBOXONE FILM (buprenorphine/naloxone)* VIVITROL (naltrexone)	BUNAVAIL (buprenorphine/naloxone) buprenorphine tablets buprenorphine/naloxone film LUCEMYRA (lofexidine) SUBLOCADE (buprenorphine soln)** ZUBSOLV (buprenorphine/naloxone)	* Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink. **Sublocade is approvable only on appeal and requires medical reasoning as to why the clinical need cannot be met with a preferred product.  VIVITROL no longer requires a PA
<b>OTIC ANTIBIOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five (5) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
CIPRO HC (ciprofloxacin/hydrocortisone) CIPRODEX (ciprofloxacin/dexamethasone) COLY-MYCIN S (colistin/hydrocortisone/ neomycin/thonzonium bromide) ofloxacin CORTISPORIN-TC (colistin/hydrocortisone/ neomycin)	ciprofloxacin <b>ciprofloxacin/fluocinolone</b> neomycin/polymyxin/HC solution/suspension OTOVEL (ciprofloxacin/fluocinolone)	
<b>PAH AGENTS – ENDOTHELIN RECEPTOR ANTAGONISTS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
LETAIRIS (ambrisentan) TRACLEER TABLET (bosentan)	ambrisentan bosentan OPSUMIT (macitentan) TRACLEER SUSP (bosentan)	
<b>PAH AGENTS – GUANYLATE CYCLASE STIMULATOR<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent from any other PAH Class before they will be approved, unless one (1) of the exceptions on the PA form is present.		



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	ADEMPAS (riociguat)	
<b>PAH AGENTS – PDE5s<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present. Patients stabilized on non-preferred agents will be grandfathered.		
sildenafil	ADCIRCA (tadalafil) REVATIO IV (sildenafil) REVATIO SUSPENSION (sildenafil) REVATIO TABLETS (sildenafil)	
<b>PAH AGENTS – PROSTACYCLINS<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent, including the preferred generic form of the non-preferred agent (if available), before they will be approved, unless one (1) of the exceptions on the PA form is present.		
epoprostenol VENTAVIS (iloprost)*	FLOLAN (epoprostenol) ORENITRAM ER (treprostiniil) REMODULIN (treprostiniil sodium) TYVASO (treprostiniil) UPTRAVI (selexipag) VELETRI (epoprostenol)	*Ventavis will only be authorized for the treatment of pulmonary artery hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms.
<b>PANCREATIC ENZYMES<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present. For members with cystic fibrosis, a trial of a preferred agent will not be required.		
CREON ZENPEP	PANCREAZE PERTZYE ULTRESA VIOKACE	
<b>PHOSPHATE BINDERS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of at least two (2) preferred agents before they will be approved, unless one (1) of the exceptions on the PA form is present.		
calcium acetate CALPHRON (calcium acetate) MAGNEBIND RX (calcium carbonate, folic acid, magnesium carbonate) PHOSLYRA (calcium acetate) sevelamer carbonate	AURYXIA (ferric citrate) ELIPHOS (calcium acetate) FOSRENOL (lanthanum) lanthanum chewable PHOSLO (calcium acetate) RENAGEL (sevelamer) RENVELA (sevelamer carbonate)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	VELPHORO (sucroferric oxyhydroxide)	
<b>PITUITARY SUPPRESSIVE AGENTS, LHRH<sup>CL</sup></b>		
<b>CLASS PA CRITERIA:</b> Unless otherwise noted, non-preferred agents are available only on appeal.		
LUPANETA (leuprolide) LUPRON DEPOT KIT (leuprolide) LUPRON DEPOT-PED KIT (leuprolide) SYNAREL (nafarelin) TRELSTAR (triptorelin) TRIPTODUR (triptorelin) VANTAS (histrelin) ZOLADEX (goserelin)	leuprolide ORILISSA (elagolix)* SUPPRELIN LA KIT (histrelin)	* Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>PLATELET AGGREGATION INHIBITORS</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
AGGRENEX (dipyridamole/ASA) BRILINTA (ticagrelor) clopidogrel dipyridamole prasugrel	clopidogrel kit dipyridamole/aspirin EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLAVIX (clopidogrel) TICLID (ticlopidine) ticlopidine ZONTIVITY (vorapaxar)	
<b>PROGESTATIONAL AGENTS</b>		
<b>CLASS PA CRITERIA:</b> Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.		
MAKENA (hydroxyprogesterone caproate) AUTO INJECTOR MAKENA (hydroxyprogesterone caproate) VIAL	hydroxyprogesterone caproate	
<b>PROGESTINS FOR CACHEXIA</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require a thirty (30) day trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
megestrol	MEGACE ES (megestrol)	
<b>PROTON PUMP INHIBITORS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require sixty (60) day trials of both omeprazole (Rx) and pantoprazole at the maximum recommended dose*, inclusive of a concurrent thirty (30) day trial at the maximum dose of an H <sub>2</sub> antagonist before they will be approved, unless one (1) of the exceptions on the PA form is present.		
omeprazole (Rx) pantoprazole  NEXIUM PACKETS (esomeprazole)** PROTONIX GRANULES (pantoprazole)**	ACIPHEX (rabeprazole) ACIPHEX SPRINKLE (rabeprazole) DEXILANT (dexlansoprazole) esomeprazole magnesium esomeprazole strontium lansoprazole Rx NEXIUM (esomeprazole) omeprazole/sodium bicarbonate (Rx) PREVACID CAPSULES (lansoprazole) PREVACID SOLUTABS (lansoprazole)** PRILOSEC Rx (omeprazole) PROTONIX DR TABLETS (pantoprazole) rabeprazole ZEGERID Rx (omeprazole/sodium bicarbonate)	*Maximum recommended doses of the PPIs and H <sub>2</sub> -receptor antagonists may be located at the BMS Pharmacy PA criteria page titled " <a href="#">Max PPI and H2RA</a> " by clicking on the hyperlink.  **Prior authorization is required for members nine (9) years of age or older for these agents.
<b>SEDATIVE HYPNOTICS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of all preferred agents in <b>BOTH</b> sub-classes before they will be approved, unless one (1) of the exceptions on the PA form is present. All agents <u>except melatonin</u> will be limited to fifteen (15) tablets in a thirty (30) day period. NOTE: WV Medicaid covers melatonin up to a maximum dose of 9 mg/day without a PA. Melatonin labeler code 51645 is preferred if available, however all NDCs are payable.		
<b>BENZODIAZEPINES</b>		
temazepam 15, 30 mg	DALMANE (flurazepam) estazolam flurazepam HALCION (triazolam) RESTORIL (temazepam) temazepam 7.5, 22.5 mg triazolam	
<b>OTHERS</b>		
melatonin zolpidem 5, 10 mg	AMBIEN (zolpidem) AMBIEN CR (zolpidem) BELSOMRA (suvorexant) chloral hydrate <b>DAYVIGO (lemborexant)</b>	Strengths of zolpidem that are non-preferred (6.25 and 12.5 mg) must be created by combining or splitting the preferred doses (5 and 10 mg) of zolpidem, if appropriate.  For treatment naïve female patients, zolpidem and zolpidem



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	EDLUAR (zolpidem) eszopiclone HETLIOZ (tasimelteon) <sup>CL*</sup> INTERMEZZO (zolpidem) LUNESTA (eszopiclone) ramelteon ROZEREM (ramelteon) SILENOR (doxepin) SOMNOTE (chloral hydrate) SONATA (zaleplon) zaleplon zolpidem ER 6.25, 12.5 mg ZOLPIMIST (zolpidem)	ER maximum dosages will be limited to 5 mg and 6.25 mg respectively per day.  *Full PA criteria may be found on the <a href="#">PA Criteria</a> page by clicking the hyperlink.
<b>SKELETAL MUSCLE RELAXANTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> See below for individual sub-class criteria.		
<b>ACUTE MUSCULOSKELETAL RELAXANT AGENTS</b>		
Chlorzoxazone (generic PARAFON FORTE) cyclobenzaprine IR 5, 10 mg methocarbamol	AMRIX (cyclobenzaprine) carisoprodol* carisoprodol/ASA* carisoprodol/ASA/codeine* chlorzoxazone (generic LORZONE) cyclobenzaprine ER cyclobenzaprine IR 7.5 mg FEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) LORZONE (chlorzoxazone) metaxalone orphenadrine orphenadrine/ASA/caffeine orphenadrine ER PARAFON FORTE (chlorzoxazone) ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol)	Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present, with the exception of carisoprodol.  *Carisoprodol requires thirty (30) day trials of each of the preferred acute musculoskeletal relaxants and Skelaxin before it will be approved.





**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>MUSCULOSKELETAL RELAXANT AGENTS USED FOR SPASTICITY</b>		
baclofen tizanidine tablets	DANTRIUM (dantrolene) dantrolene tizanidine capsules ZANAFLEX (tizanidine)	Non-preferred agents require thirty (30) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.
<b>STERIODS, TOPICAL</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require five (5) day trials of one (1) form of <b>EACH</b> preferred unique active ingredient in the corresponding potency group before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>VERY HIGH &amp; HIGH POTENCY</b>		
betamethasone dipropionate cream betamethasone valerate cream betamethasone valerate lotion betamethasone valerate oint clobetasol propionate cream/gel/ointment/solution clobetasol emollient clobetasol propionate shampoo fluocinonide gel triamcinolone acetonide cream, ointment triamcinolone acetonide lotion	amcinonide APEXICON (diflorasone diacetate) APEXICON E (diflorasone diacetate) betamethasone dipropionate gel, lotion, ointment BRYHALI LOTION (halobetasol) clobetasol lotion clobetasol propionate foam CLOBEX (clobetasol propionate) CLODAN KIT (clobetasol propionate) CLODAN SHAMPOO (clobetasol propionate) CORMAX (clobetasol propionate) desoximetasone cream/gel/ointment diflorasone diacetate DIPROLENE (betamethasone dipropionate/propylene glycol) DIPROLENE AF (betamethasone dipropionate/propylene glycol) DIPROSONE (betamethasone dipropionate) fluocinonide cream fluocinonide ointment fluocinonide solution fluocinonide/emollient halcinonide HALAC (halobetasol propionate) halobetasol propionate HALOG (halcinonide) HALONATE (halobetasol propionate) KENALOG (triamcinolone acetonide) LEXETTE FOAM (halobetasol) LIDEX (fluocinonide)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LIDEX-E (fluocinonide) OLUX (clobetasol propionate) OLUX-E (clobetasol propionate/emollient) PSORCON (diflorasone diacetate) SERNIVO SPRAY (betamethasone dipropionate) TEMOVATE (clobetasol propionate) TEMOVATE-E (clobetasol propionate/emollient) TOPICORT CREAM, GEL, OINTMENT (desoximetasone) TOPICORT SPRAY (desoximetasone) TOVET FOAM (clobetasol) ULTRAVATE (halobetasol propionate) ULTRAVATE PAC cream ULTRAVATE X (halobetasol propionate/lactic acid) VANOS (fluocinonide)	
<b>MEDIUM POTENCY</b>		
fluticasone propionate cream, ointment mometasone furoate triamcinolone acetonide 0.025% and 0.1% cream	ARISTOCORT (triamcinolone) BESER LOTION (fluticasone) BETA-VAL (betamethasone valerate) betamethasone valerate foam CLODERM (clocortolone pivalate) clocortolone cream CORDRAN/CORDRAN SP (flurandrenolide) CUTIVATE (fluticasone propionate) DERMATOP (prednicarbate) ELOCON (mometasone furoate) fluocinolone acetonide cream, ointment, solution fluticasone propionate lotion hydrocortisone butyrate cream hydrocortisone butyrate ointment, solution hydrocortisone valerate LOCOID (hydrocortisone butyrate) LOCOID LIPOCREAM (hydrocortisone butyrate/emollient) LUXIQ (betamethasone valerate) MOMEXIN (mometasone) PANDEL (hydrocortisone probutate) prednicarbate	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TOPICORT LP (desoximetasone) TRIDERM (triamcinolone acetonide) WESTCORT (hydrocortisone valerate)	
<b>LOW POTENCY</b>		
<b>DERMA-SMOOTH FS (fluocinolone acetonide)</b> hydrocortisone acetate (Rx, OTC) hydrocortisone cream (Rx, OTC) hydrocortisone lotion OTC hydrocortisone ointment (Rx, OTC) hydrocortisone solution OTC hydrocortisone-aloe cream OTC hydrocortisone-aloe ointment OTC	ACLOVATE (alclometasone dipropionate) alclometasone dipropionate AQUA GLYCOLIC HC (hydrocortisone) CAPEX (fluocinolone acetonide) DESONATE (desonide) desonide cream, ointment desonide lotion DESOWEN (desonide) fluocinolone oil hydrocortisone/mineral oil/petrolatum hydrocortisone acetate/urea hydrocortisone lotion hydrocortisone/aloe gel LOKARA (desonide) PEDIADERM HC (hydrocortisone) PEDIADERM TA (hydrocortisone) SCALPICIN OTC (hydrocortisone) SYNALAR (fluocinolone) TEXACORT (hydrocortisone)	
<b>STIMULANTS AND RELATED AGENTS</b>		
<b>CLASS PA CRITERIA:</b> A PA is required for adults eighteen (18) years of age or older.		
Non-preferred agents require a thirty (30) day trial of at least one preferred agent in the same subclass and with a similar duration of effect and mechanism of action, unless one (1) of the exceptions on the PA form is present. <b>NOTE:</b> Non-preferred agents will NOT be “grandfathered” for adults. Children under the age of 18 may continue their current therapy until the end of the school year after which they will be required to switch to a preferred agent.		
<b>AMPHETAMINES</b>		
amphetamine salt combination ER amphetamine salt combination IR dextroamphetamine ER dextroamphetamine IR VYVANSE CHEWABLE (lisdexamfetamine) VYVANSE CAPSULE (lisdexamfetamine)	ADDERALL (amphetamine salt combination) ADDERALL XR (amphetamine salt combination) ADZENYS XR ODT (amphetamine) ADZENYS ER SUSP (amphetamine) DESOXYN (methamphetamine) DEXEDRINE ER (dextroamphetamine) DEXEDRINE IR (dextroamphetamine) dextroamphetamine solution DYANAVEL XR SUSP (amphetamine) EVEKEO (amphetamine)	<b>In addition to the Class Criteria:</b> Thirty (30) day trials of at least three (3) antidepressants are required before amphetamines will be authorized for depression.  *Mydayis requires a 30-day trial of at least one long-acting preferred agent in this subclass and a trial of Adderall XR.



**BUREAU FOR MEDICAL SERVICES  
WEST VIRGINIA MEDICAID  
PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE  
01/01/2021  
Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	EVEKEO ODT (amphetamine) methamphetamine MYDAYIS (dextroamphetamine/amphetamine salt)* PROCENTRA solution (dextroamphetamine) ZENZEDI (dextroamphetamine)	
<b>NON-AMPHETAMINE</b>		
atomoxetine CONCERTA (methylphenidate) clonidine IR dexmethylphenidate IR FOCALIN XR (dexmethylphenidate) guanfacine ER guanfacine IR methylphenidate IR methylphenidate ER tablet (generic RITALIN SR) methylphenidate solution QUILLICHEW ER (methylphenidate) QUILLIVANT XR (methylphenidate)	ADHANSIA XR (methylphenidate) APTENSIO XR (methylphenidate) clonidine ER COTEMPLA XR ODT (methylphenidate) DAYTRANA (methylphenidate) dexmethylphenidate XR FOCALIN IR (dexmethylphenidate) INTUNIV (guanfacine extended-release) JORNAY PM (methylphenidate) KAPVAY (clonidine extended-release) METHYLIN SOLUTION (methylphenidate) methylphenidate CD methylphenidate chewable tablets methylphenidate ER 24 tablet (generic CONCERTA) methylphenidate ER solution methylphenidate LA capsule RITALIN (methylphenidate) RITALIN LA (methylphenidate) STRATTERA (atomoxetine)*	* Strattera is limited to a maximum of 100 mg per day.
<b>NARCOLEPTIC AGENTS</b>		
armodafinil <sup>CL</sup> modafinil <sup>CL</sup>	NUVIGIL (armodafinil) PROVIGIL (modafinil) SUNOSI (solriamfetol)* WAKIX (pitolisant)**	* Sunosi is approvable only with documentation of treatment failure after 30-day trials of both armodafinil and modafinil.  **Wakix is approvable only with documentation of treatment failure after 30-day trials of armodafinil, modafinil and Sunosi.
<b>TETRACYCLINES</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require ten (10) day trials of each preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.		
doxycycline hyclate capsules doxycycline hyclate 100 mg tablets	ADOXA (doxycycline monohydrate) demeclocycline*	*Demeclocycline will be authorized for conditions caused by susceptible strains of organisms designated in the product



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
doxycycline monohydrate 50, 100 mg capsules minocycline capsules	DORYX (doxycycline hyclate) doxycycline hyclate 75, 150 mg tablets doxycycline hyclate tablet DR 75, 100, 150, 200 mg doxycycline hyclate tablet DR 50 mg doxycycline monohydrate 40, 75, 150 mg capsule doxycycline monohydrate tablet doxycycline monohydrate suspension DYNACIN (minocycline) MINOCIN (minocycline) minocycline ER capsules minocycline tablets MINOLIRA ER (minocycline) MORGIDOX KIT (doxycycline) ORACEA (doxycycline monohydrate) SOLODYN (minocycline) tetracycline VIBRAMYCIN CAPSULES, SUSPENSION, SYRUP (doxycycline) XIMINO (minocycline)	information supplied by the manufacturer. A C&S report must accompany this request. Demeclocycline will also be authorized for SIADH.
<b>ULCERATIVE COLITIS AGENTS<sup>AP</sup></b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred dosage form or chemical entity before the corresponding non-preferred agent of that dosage form or chemical entity will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>ORAL</b>		
APRISO (mesalamine) ASACOL HD (mesalamine) balsalazide PENTASA (mesalamine) 250 mg PENTASA (mesalamine) 500 mg sulfasalazine	AZULFIDINE (sulfasalazine) COLAZAL (balsalazide) DELZICOL (mesalamine) DIPENTUM (olsalazine) GIAZO (balsalazide) LIALDA (mesalamine) mesalamine UCERIS (budesonide)	
<b>RECTAL</b>		
CANASA (mesalamine) mesalamine	DELZICOL DR (mesalamine) mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine) UCERIS (budesonide)	



**BUREAU FOR MEDICAL SERVICES**  
**WEST VIRGINIA MEDICAID**  
**PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA**  
 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL.

**EFFECTIVE**  
**01/01/2021**  
**Version 2021.1a**

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
<b>VASODILATORS, CORONARY</b>		
<b>CLASS PA CRITERIA:</b> Non-preferred agents require thirty (30) day trials of each preferred dosage form before they will be approved, unless one (1) of the exceptions on the PA form is present.		
<b>SUBLINGUAL NITROGLYCERIN</b>		
nitroglycerin spray (generic NITROLINGUAL) nitroglycerin sublingual NITROSTAT SUBLINGUAL (nitroglycerin)	GONITRO SPRAY POWDER (nitroglycerin) nitroglycerin spray (generic NITROMIST) NITROLINGUAL SPRAY (nitroglycerin) NITROMIST (nitroglycerin)	

DRAFT